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ABSTRACT
Chronic exposure to environmental carcinogens may trigger development of
sporadic breast cancer, a multistep tumorigenesis process involving aggregation of
genetic and epigenetic alterations, resulting in a serial progression from a non-cancerous
to precancerous stage and eventually malignant breast cancer. In this study, I used a
cellular model that simulates induction and progression of chronic breast cell
carcinogenesis using concentrations of environmental carcinogens which are achievable
in blood or plasma. Process of carcinogenesis was measured by certain detectable
constitutive and transient end points including acquisition of cancer-associated properties,
increased ROS prodiction, cell proliferation, DNA damage and activation of Erk-Nox
pathway which could be targeted by non-cytotoxic dosages of dietary compounds.
Triclocarban (TCC) is an antimicrobial agent present in personal care products.
This study was designed to investigate the ability of TCC to act as a co-carcinogen and
therefore induce premalignant breast cell carcinogenesis and enhance 2-Amino-1-methyl6-phenylimidazo(4,5-b)pyridine (PhIP)-induced breast cell carcinogenesis in MCF10A
cells. My results showed that repeated treatments with TCC induced cancer-associated
properties of reduced dependence on growth factors and anchorage-independent growth
in MCF10A cells. Concurrently, there was increased ROS production, cell proliferation
and upregulation of Erk-Nox pathway in response to single as well as long term exposure
to TCC. Curcumin, a polyphenolic component extracted from the rhizome, Curcuma
longa, was able to suppress these transient and constitutive endpoints induced in breast
cells exposed to TCC. MCF10A cells were also subjected to either individual or
combined TCC and PhIP exposure. Cells co-treated with TCC and PhIP had significantly

vii
higher levels of cancer-associated properties, ROS production, cell proliferation and ErkNox pathway activation as compared to cells treated with PhIP alone. The transient and
constitutive endpoints induced by co-treatement with TCC and PhIP were significantly
suppressed by mimosine, a non protein amino acid isolated from Mimosa pudica and
Ergosterol, a sterol found in cell membranes of fungi. These results proved that TCC has
the ability to induce breast cell premalignancy and enhance breast cell carcinogenesis
induced by PhIP in MCF10A cells. Furthermore, curcumin, ergosterol and mimosine
could play promising roles in prevention of sporadic breast cancer.
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Chapter 1

Background and Overview

2
1.1 Breast cancer
According to National Cancer Institute and American cancer society, cancer is a term
used for a group of diseases in which abnormal cells divide without control and are able
to invade other parts of body through the blood vascular and lymphatic systems [1].
There are many different types of cancers which can arise in any organ of the body but
share the common characteristic of uncontrolled growth. Human breast is a glandular
structure divided into lobules which secrete milk to be delivered via ducts to the nipple.
Fat, connective tissue, and lymphatics constitute the rest of breast. Cancer of breast is
broadly divided into two subtypes: those originating from ducts are known as ductal
carcinomas; those originating from lobules are known as lobular carcinomas. Breast
cancer is the most common type of cancer among women worldwide. Cases of breast
cancer in developed countries far outnumber those in the developing countries
(Figure1.1). Breast cancer is also the most common type of cancer and second leading
cause of deaths among American women after lung cancer [1]. It is projected by
American cancer society, that approximately 232,340 cases of invasive breast cancer and
64,640 new cases of in situ breast cancer would be diagnosed in 2013 [1]. In 2013, it is
estimated that there would be about 39,620 breast cancer related deaths among women
[1]. Also, about 2,240 cases of invasive breast cancer are expected to occur among men
in 2013 which is about 1% of all breast cancer cases and 410 deaths are projected to
occur in men because of breast cancer this year [1].
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Figure 1.1: Worldwide incidence and mortality rates of breast cancer
Breast Cancer 2008 Estimates, World Age
Age-Standardized
Standardized Incidence and Mortality Rates
per 100,000 Population, Females, World Regions
Modified from cancer research UK, http://www.cancerresearchuk.org/cancerinfo/cancerstats/world/breast-cancer
cancer-world/ assessed April, 2013
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1.1.1 Stages of breast cancer
The various stages of breast cancer are classified as follows (Figure 1.2):
Stage 0: This stage is also called as carcinoma in situ and is of the following three types:
a) Paget's disease of the nipple: In this condition abnormal cancerous cells are
confined to the nipple.
b) Ductal carcinoma in situ (DCIS): cancer cells are found in the ductular lining of
the breast tissue and the cells have not invaded the surrounding tissues.
c) Lobular carcinoma in situ (LCIS): It is the cancer affecting lobules of breast and
cancerous cells do not invade surrounding tissue.
Stage I
Stage I is further subdivided into stages IA and IB.
In the former sub stage, the tumor size is 2 centimeters or smaller. The tumor is present
only in the breast tissue and has not spread outside the breast and has not invaded the
lymphnodes. In the second substage tumor clusters ranging from 0.2 millimeters - 2
millimeters may be found in the adjoining lymph nodes.
Stage II: Here the tumor size is larger than the previous stage and varies between from 2
to 5 mm but has not yet spread to other far away locations but maybe found in lymphnodes of the adjoining area like the axillary lymph nodes.
Stage III: Tumor size is larger than stage II and is larger than 5 mm. Tumor clusters
measuring 0.2-2mm may be found in the adjoining lymph-nodes or lymph-nodes of collar
bone. Tumors regardless of their size that have managed to infiltrate and reach the chest
wall or that reach breast skin are also categorized as stage III breast cancer.
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NORMAL BREAST

STAGE II BREAST CANCER

STAGE I BREAST CANCER

STAGE III BREAST CANCER

STAGE IV BREAST CANCER

Modified from Mayo Clinic website
Figure 1.2. Stages of breast cancer

http://www.mayoclinic.com/
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Stage IV:
It is known as the metastasizing stage of breast carcinoma. Cancer cells are present in
surrounding lymph nodes and have also invaded the distant parts of the body, such as the
lungs, distant lymph nodes, skin, bones, liver, or brain.

1.1.2 Classification of breast cancer:
Breast cancer is disease entity which encompasses varied subtypes on the basis of
distinctness of patho-morphological characteristics and clinical outcome. Newer
diagnostic tools such as immunohistochemistry, cytogenetics and microarray are
employed for accurate diagnosis and prognosis [2, 3, 4, 5 , 6]. Complementary DNA
microarray analysis has been used to classify breast cancer into five major subtypes
which are as follows: Luminal A, Luminal B, Normal breast like, Her2 and basal like
breast cancer. However, newer subtypes have also been recently added [2, 6,] (Table 1).
This categorization takes into account the two major types of epithelial cells found in
human mammary gland- luminal epithelial cells and basal epithelial cells, the latter are
also known as myo-epithelial cells. These two types of epithelial cells can be
differentiated immuno-histochemically on the basis of expression of different kinds of
hormone receptors by these cells. For example, luminal cells express estrogen receptors
(ER receptors) or progesterone receptors (PR receptors) and are found to be positive for
cytokeratins 8/18. On the contrary the basal cells are devoid of estrogen receptor. The
latter are however, found to be positive for the expression of cytokeratins 5/6, and 17.
The basal type of breast cancers are also sometimes called as triple negative breast
cancers because they are found to lack Human epidermal growth factor receptor 2 (HER2
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receptors) too. Nonetheless there are some recognized differences between the basal type
breast cancers and triple negative breast cancers. Approximately seventy five percent of
basal like cancers have been found to be triple negative but the remaining twenty five
percent of the basal cancers have been found to exhibit either the cell surface receptor
Her2 or the two hormone receptors. Around three fourths of the triple negative breast
cancers are considered as basal like breast cancers [2, 7]. Triple negative character is
exhibited by the following breast cancer subtypes: basal like cancers, normal breast like
tumors and breast cancers occurring due to the deficiency or abnormality of BRCA1
(Breast cancer 1, early onset) gene. Triple negative cancers are defined as tumors that
lack ER, PR and HER2 expression. Moreover, triple negative cancers account for
approximately ten to twenty-five percent of all the cancers of the breast tissue [8, 9] and
can show different kinds of histologic patho-morphology. Triple negative cancers are
found to occur predominantly in younger women less than fifty years of age and women
belonging to African American ethnicity.

1.1.3 Risk factors for Breast cancer:
A risk factor may be defined as any stimulus that increases a person's chance of getting a
disease. Different risk factors are associated with different types of cancers. There are
some known risk factors for breast cancer. According to National Cancer Institute, 2011,
being born as a female is an overwhelming risk factor for the development of breast
cancer in women [1]. Many of the other risk factors for breast cancer include the
following: age at menarche, age at first live birth, and age at menopause. Age is a
significant risk factor with the chances of developing breast cancer increase with
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increasing age in women. Only about 6% of breast cancers in the United States are
known to occur in women under the age of forty years. However, in contrast to the
women who are more than forty years of age, younger women are often found to be less
affected with breast cancer which is generally a much more severe disease in younger
women with a poorer prognosis and which generally progresses to advanced stages.
Also, these younger women affected with breast cancer have higher rates of breast cancer
recurrence and breast cancer related mortality [10]. Sixty seven percent of the cases
categorized as invasive breast cancers occur in women who are fifty five years or are
older. Breast cancer seldom occurs in females younger than twenty five years of age, but
there can be an exception to this fact when breast cancer runs in the family. Hormonal
levels influence the development of breast cancer and are important risk factors for the
development of this disease. Many factors are known to influence proliferation and
growth of cells of mammary gland. The most important among them are estrogen and
progestins. Others might include transforming growth factor alpha and epidermal growth
factor family proteins [11]. Levels of endogenous steroid sex hormones are strong
determinants of breast tumor development risk. Infact, female menopausal breast cancer
patients were found to have higher levels of steroid hormones including androgens and
estrogens in their circulation [12]. Chances of acquiring mammary gland neoplasia may
be affected by other hormone- related events. There is an elevation in the risk of breast
cancer development for a small time period following delivery of a newborn. After that
there is lessening of predisposition to developing mammary neoplasia for an extended
period of time post-delivery, especially in case of younger females [13, 14, 15]. In one
study, women who experienced a first full-term pregnancy before the age of twenty
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years, had their chances of developing breast cancer reduced by half when compared to
women who never became pregnant. The former also had significantly lower chances of
breast cancer development than the females who successfully completed their first
pregnancy at the age of 35 years or later [16, 17]. Age at which women start their
menstruation cycles, also affects breast cancer development risk later in their lives.
Women reaching puberty at an earlier age, for example, if they attained puberty when
they turned 11 years or an earlier age, were found to be more at risk of developing breast
cancer by about 20% as compared to women who reached puberty when they turned 14
years or later [18]. Women reaching menopause at a later age than that is normal for
most women also have significant chances of developing breast cancer. Obese
postmenopausal women have been shown to be more predisposed to develop breast
cancer [19]. In addition, there are other factors associated with reproduction that may
also influence breast cancer development. Ovarian hormones may influence
development of breast cancer. Ovariectomy is known to reduce breast cancer risk by
around three quarters. This kind of reduction can be greatly influenced by a women’s
age, her weight, and number of children she bears. It was seen that ovariectomy was
most useful in reducing breast cancer development risks in cases of younger women who
were not overweight and didn’t have any children [20, 21]. The removal of uterus and
ovaries was also shown to reduce the risk of breast cancer [22]. Individual genetic
makeup also predisposes women for developing breast cancer. Moreover, the inheritance
of defective genes has the capability to enhance the potential of known mutagenic agents
and factors that are known to promote growth and proliferation of breast tissue ultimately
leading to tumorigenesis in breast tissue. About 5%-10 of breast cancers are known to be
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hereditary in nature and a prior familial history of breast cancer i.e. women with other
close relatives afflicted with breast cancer like mother, siblings or aunts, predisposes
them towards mammary gland neoplasia. Mutations in the following two genes: BRCA1
& BRCA2 accounts for the majority cases of hereditary breast cancers [23, 24, 25]. Even
though women with a familial history of breast cancer are more predisposed to breast
cancer development, yet only one in five women with relatives affected with breast
cancer has been shown to carry germ line mutations in BRCA1 and BRCA2 genes [26,
27]. Mutations affecting BRCA1 are much more common than those affecting the related
BRCA2 gene [28]. Mutations in the latter gene have been associated with breast cancer
development in men [29].
Most of the women afflicted with Li- fraumeni syndrome are known to suffer from breast
cancer. In women suffering from Li- fraumeni syndrome, germ line mutations are found
in P53, which is an important tumor suppressor gene [30]. Women younger than twenty
years of age who underwent radiation for treatment of other types of cancers were shown
to have a high risk of up to 20% to 30% more, for the development of breast cancer as
late as twenty to thirty- years after radiation therapy [31]. Exposure to ionizing radiation
enhances the breast cancer development risk [32]. Other surgical and medical procedures
utilizing radiation as diagnosis or treatment have been linked to higher risks of breast
cancer development [33]. Moreover, women who are known to be heterozygotes for
ataxia-telangiectasia gene possess enhanced predisposition to develop malignancies of
the breast tissue [34]. Race is an important risk factor for the development of breast
cancer. White women are more at risk of developing breast cancer as compared to the
women of African-American, Hispanic, and Asian origin, even though the breast cancers
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affecting black women have been found to be highly aggressive. Obesity and being
overweight are other important factors associated with increased risks of breast tissue
cancers [35]. Higher levels of leptin hormone secreted by adipose tissue cells, especially,
those forming breast tissue microenvironment are postulated to influence development of
breast cancer by aiding in angiogenesis and can also enhance metastasis and mortality
due to breast cancer in obese women [35]. Obese women are not only predisposed to
develop breast cancer but are also likely to have a poorer prognosis of the disease [36].
Obesity also happens to be a risk factor for women for breast cancer recurrence. Being
overweight can not only increase the risk of the breast cancer recurrence in women who
have had the disease, but it also is known to increase the risk of breast cancer
development among postmenopausal women. Researchers have tried to shed light on the
probable link between obese post-menopause state and breast cancer in recent years [19],
where they have found that systemic and local mammary metabolism which gets
upregulated in obese subjects, leads to activation of progesterone receptors which in turns
aids in the development of post-menopausal PR positive breast cancer. Other factors like
the use of hormone replacement therapy, alcohol consumption, cigarette smoking and
sedentary lifestyle with no physical activity, also enhance the risk for development of
breast cancer which will be discussed in the subsequent sections. Since less than ten
percent of breast cancer is of hereditary origin and more that 90% is attributable to nongenetic factors, therefore, it becomes imperative to study in detail, the role played by
environment agents in predisposing women to develop breast cancer [37].
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1.1.3.1 Environmental Carcinogens:
Carcinogens are defined as any of the natural or synthetic substances that have the
potential to cause cancer. Humans are subjected to an exposure from a wide range of
chemicals from the environment each day through air, water, soil and food. Also,
humans are exposed to hazardous chemicals in their work environment on a day today
basis. Even, individual lifestyle factors are important contributors affecting our general
health and predisposition to diseases like breast cancer [38]. Further as stated above,
greater than 90% cases of breast cancer are non-hereditary and are classified as sporadic
breast cancers [37]. In order to formulate an effective strategy for prevention and control
of sporadic cancers, knowledge of everyday chronic exposures to low doses of
environmental pollutants is of utmost importance especially for understanding
pathogenesis of carcinogenesis process which ca then be used to devise preventive
measures that can intervene with the process of carcinogenesis attributable to
environmental agents. The American Cancer Society [1] has put forth a classification of
some of the environmental factors which possess the potential to cause the non-hereditary
form of breast (Table 2) cancer which are classified into the following categories
according to their mode of exposure: carcinogens related to lifestyle (smoking, alcohol,
diet, sedentary life style), naturally occurring substances (ultraviolet rays, infectious
agents, radon), chemicals found in the home and workplace, infectious agents,
carcinogens coming through medical treatments (hormone replacement, immunesuppressing treatments, exposure to radiation) and others.
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1.1.3.2 Risk factors related to lifestyle
Risk factors associated with our lifestyle in general are not the causative or etiological
factors for breast cancer but act as predisposing factors. High dosage exposure to
carcinogens can be associated with a particular occupation or accidental exposure to a
potentially hazardous material. Individual behavioral peculiarities such as being under
any kind of addiction can also expose human body to direct cancer causing agents i.e.
carcinogens [39, 40]. In the same study it was also noted that among other factors,
habitual smoking, heavy drinking, unhealthy and imbalanced diet consumption, obesity
and complete absence of any form of physical activity are prominent contributors for
cancer in high-income countries [39].

1.1.3.2.1 Tobacco smoking
Cigarette smoking is a well-known and significant risk factor for initiation and
progression of carcinogenesis [41]. Thousands of components found in cigarette smoke
have been found to be mutagenic since it contains both promoters as well as initiators of
carcinogenesis process and hence tobacco smoke can be considered as a complete
carcinogen [40]. Habitual smoking is a major cause of cancer mortality worldwide and
either directly causes or predisposes humans towards many different types of cancers
such as those affecting lungs, upper digestive tract, esophagus, stomach, pancreas, liver,
bladder, kidney, mammary and cervical cancers, bone marrow [English et al 1995.
Despite the fact that there is no direct evidence of smoke originating from tobacco acting
as a direct cause of breast cancer, recent reports suggest that components of smoke from
tobacco, such as NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) and
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Benzoapyerene, can together play the role of co-carcinogens in sporadic breast cell
carcinogenesis [42]. Moreover, more recently, evidence has accumulated to link chronic
habitual smoking and being a smoker from a very young age with risk of breast neoplasia
[43]. In addition, passive smoking may increase the risk of breast cancer in postmenopausal women [43].

1.1.3.2.2 Alcohol consumption
Role of alcohol as a carcinogen is under constant scrutiny. Habitual drinking can play the
role a risk factor for carcinogenesis of various organs as was revealed by meta-analysis of
over two hundred studies [44]. Alcohol has been classified as a human carcinogen.
Alcohol can promote carcinogenesis by various ways which may include the following:
induction of enzymes like CYP2E1, an enzyme involved in the metabolism of
xenobiotics in the body, to generate carcinogens from pro-carcinogens, activation of
MAPK signaling, cellular oxidative stress, and in breast cells alcohol may cause increase
response to endogenous estrogens [45]. Moreover, data from several epidemiological
studies shows that alcohol consumption is indeed associated with increased risk of breast
cancer occurrence [46]. It has also been shown to act as a potentiator of carcinogenic
effects of others like tobacco [46]. Some researchers however, consider it only as a
tumor promotor or a co-carcinogen [47].

1.1.3.2.3 Diet
With busier and high tech lifestyles of the present day, quality of diet, especially in
thedeveloped world, has deteriorated and has become ever more unhealthy with fast food
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and fried food forming major chunk of food. Unbalanced diet which is high in fat,
protein and carbohydrates and low in fiber is associated with high prevalence of cancers
especially that affecting colon, prostate, endometrium and breast. But this can be
countered by a regular balanced consumption of different kinds of natural antioxidants
present in a wide array of fruits and vegetables [48, 49]. Diet can also be an unwanted
source of carcinogens. Among the various dietary carcinogens , 2-amino-1-methyl-6phenylimidazo [4,5-b]pyridine (PhIP), is one of the most abundant heterocyclic amines,
found in high-temperature cooked meats or well done meats such as grilled/barbecued
meats [50, 51, 52]. Consumption of well-done meats containing PhIP has been suggested
to act as a risk factor for development of breast cancer in some epidemiological studies
[53].

1.1.3.2.4 Overweight, obesity and sedentary lifestyle
Obesity is touted as an important risk factor for cancer. Some authors have suggested
that obesity can exacerbate cancer mortality [54]. Rates of breast cancer in western
world are considerably higher than that found in the developing world. But, the risk of
breast cancer in immigrant populations after their settlement in US has steadily risen after
migration which is mostly attributed to changed life style after migration. Even breast
cancer risk in relatively developed Asian countries like Japan and Taiwan, has also
increased in recent times. A prospective cohort study suggested that energy imbalance
with high dietary intake and less consumption by means of physical inactivity may be
associated with high risk of breast cancer particularly in premenopausal women [55].
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1.1.3.3 Naturally occurring substances:

1.1.3.3.1 Ultraviolet rays
Ionizing radiation and ultraviolet rays have the potential to damage DNA and cause
cancer. UV irradiation is one of the foremost risk factors for the development of skin
cancer [56, 57, 58]. Tumors induced in response to UV radiation exposure, have shown a
sharp rise in the United States, Europe and Australia [59]. Recently, however, exposure
to UV radiation has been associated with a decreased risk of cancer in children [60]
.
1.1.3.3.2 Infectious agents
The role of viruses first came to the fore when Bitters in 1936, found that a filterable
agent, after being transmitted via milk caused breast cancer in suckling mice [61], which
was later identified as a retrovirus. Since then there have been efforts to find whether
there is a virus that specifically causes human viral mammary tumors but there is not
concrete evidence of a direct link in this regard [62]. A significant 15% to 20% of
neoplastic conditions are known to be caused by infectious agents including viruses,
bacteria and parasites [63]. Some infections can enhance tumorigenicity induced by
another primary agent wherein they themselves only cause immunosuppression related to
infection induced inflammation. Certain infectious agents are known to be causative
agents of cancer for example, H. pylori ,a bacterium found in stomach, is an important
risk factor for the subsequent development of stomach cancer [64] and human papilloma
virus (HPV) is known to be associated with cervical cancer [65]. Recent research has
uncovered newer emerging pathogens capable of causing neoplasia in humans [66].
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Moreover recent studies show that polycyclic aromatic hydrocarbons (PAH) and
tumorigenic viruses can cause carcinogenic synergy [67]. In the later study it was shown
that in response to PAH there was ROS-induced DNA damage and, human polyoma virus
T antigen expressing cells impaired DNA repair, to potentiate overall the carcinogenicity.

1.1.3.3.3 Radon
Radon, a colorless, odorless, radioactive gas produced due to radioactive decay of
uranium or thorium, is the second leading cause of lung cancer, after smoking. Radon is
responsible for about 21,000 lung cancer deaths in US every year [68]. Radon is found in
soil rock; even it is present indoors, with the maximal levels found to be present in
basements areas from where it seeps via gaps in floors or walls. Even recent studies have
found links of levels of radon exposure and lung cancer [69]. Recently, radon related
lung cancers were found to occur more frequently among smokers [70].

1.1.3.4 Chemicals in the home and workplace
As per National Institute of Environmental Health Sciences description, chemical
carcinogens are substances and circumstances that either are "known" or are "reasonably
anticipated" to produce cancer. There is a long list of chemicals that are considered as
carcinogens. Certain pollutants of the environment are thought to behave like hormones
for example organo-chlorine pesticides can exhibit estrogen like activity and therefore
might induce or influence development of breast cancer [71 ]. Chemicals such as
benzene, auto exhaust, cigarettes, industrial processes and some consumer goods, have
been associated with development of cancers while many others are being researched for
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possessing potential carcinogenic activity. Some important carcinogenic chemicals are
listed as under:

1.1.3.4.1 Diesel exhaust: This is produced by diesel motor driven vehicles used at
construction sites or those used on roads and on farms. It not only causes environment
pollution but also has been linked to the risk of lung cancer development [72, 73].
Inhalation of passive smoke from the surrounding environment, which was found to
contain several thousand chemicals, out of which greater than sixty have been associated
with the risk of developing cancer including lung cancer [74, 75, 76]. Asbestos is another
chemical, exposure to which predisposes people to developing several diseases of lungs
including cancer, mesothelioma, laryngeal cancer and gastrointestinal cancers and over
200, 000 deaths were expected to occur in 2010 due to asbestos induced cancers of the
lung and mesothelium. The total deaths in US due to asbestos-related lung cancer,
mesothelioma and asbestosis from workplace exposure resulted is estimated to be over
200,000 for year 2010 [77, 78]. Recent studies have shown people working in ship
breaking business are predisposed to several types of cancers including oral and
nasopharyngeal tumors, lung cancer and liver cancers because of possible exposure to
asbestos and other metals [79].

1.1.3.5 Medical treatments (hormone replacement, immune-suppressing treatments)
To treat postmenopausal discomfitures, hormone replacement therapy (HRT) is widely
used in women. It has also been used for treatment of osteoporosis and ailments of
cardiovascular impaired cognitive functions and dementia in menopausal women.
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However, several studies have raised concerns over its purported effectiveness in such
treatments [80, 81]. Some studies report that use of hormones can increase the risk of
breast cancer [82]. This type of therapy can increase the risk of other types of cancers
like ovarian, colorectal and brain cancers [83, 84, 85]. In case of organ or graft transplant
patients, immunosuppressive drugs are administered to reduce the chances of graft
rejection. But since these agents are known to lower the immunity in the patients, such
patients are highly at risk to contact infections and even cancers, [86, 87]. Since extreme
immunosuppression has been suspected to be related to certain drugs used for treating
cancers of skin and lymphoma [81, 88], these drugs should be used with extreme care and
caution.

1.1.3.6 Others
Silica, nickel and cobalt have been related to cancer causation [89]. Moreover, some
other chemicals used in day to day life have been suspected to play important role in
carcinogenesis process which includes among others the following: antiperspirants,
talcum powder, hair dyes, and cosmetics [90]. However, some researchers suggest that a
pronounced carcinogenic effect only is reflected if the exposure occurs at an occupational
level [91]. In addition, there are other well known carcinogens like 4(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene (B[a] P) that
can affect breast cancer development [42].
In this discussion of carcinogens so far, I have reviewed only some of the chemicals
known to be carcinogenic. Moreover, apart from the chemicals that are known
carcinogens, there are many other chemicals whose carcinogenic potential is unknown.
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In this study, I use two chemicals to which human bodies are exposed continuously on an
everyday basis: Triclocarban (TCC), or 3, 4, 4’-trichlorocarbanilide, an antimicrobial
agent and the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine or
PhIP.

1.1.3.7 Triclocarban
Triclocarban (TCC), or 3,4,4'-trichlorocarbanilide (Figure 1.3), is an antibacterial agent
commonly used in personal care products such as disinfectants, soaps, body washes
deodorants, detergents, cleansing lotions, wipes etc [92]. Antibacterial activity is
attributed to its ability to disrupt cellular membranes [93] by inhibition of the enzyme
enoyl-acyl carrier protein reductase (ENR) which is only present in some bacteria and
fungi. The enzyme prevents the synthesis of fatty acids needed for building cell
membranes and other vital functions. Many researchers have detected the presence of
TCC in surface waters and sewage sludge [94, 95, 96, 97, 98]. These studies therefore
suggest that the widespread use of personal care products containing TCC may pose risks
for human health. But, adverse effects of trichlocarban on humans are largely unknown.
A study involving rats [99], revealed that continuous incorporation of TCC in a diet at
3,000 or 10,000 ppm for six months lead to degenerative changes in seminiferous tubules
and oligospermia. However, testicles didn’t develop any pathological changes in rats fed
TCC at 1000 ppm. In a study conducted in 1979 [100], a group of rats was fed various
levels of a diet containing TCC and 3-trifluoromethyl-4, 4’- dichlorocarbanilide in the
ratio of 2:1.
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Triclocarban

PhIP

Figure 1.3 Chemical structures of carcinogens
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The cohort that was fed the diet comprising of mixture at 0.25% was found to exhibit a
reduction in the conception rate, number of live births and survival rate among those that
were born. Recent research has shown that TCC can act as an endocrine disrupter. It has
been shown to augment the activities of certain steroid hormones [101]. In recent in vitro
studies, which used reporter gene assays, it has been reported that although TCC did not
possess any agonist activity for estrogen receptor or androgen receptor in recombinant
estrogen or androgen responsive cells, yet in the presence of estrogen and testosterone,
TCC was found to amplify their hormonal actions. Another study by Chen et al [102],
reported that in the presence of testosterone hormone, TCC was found to enhance
testosterone’s hormonal effects. However, TCC failed to affect protein expression of
androgen receptor or AR mediated signaling. Also, TCC didn’t interfere with
testosterone for its binding to androgen receptor. Simultaneous administration of
testosterone and TCC in diet to castrated male rats at 0.25% for 10 days lead to a
significant increase in weight of accessory sex organs in comparison to rats that were
exposed to either testosterone or TCC alone. TCC was shown to increase embryo
production in freshwater mud snails, in a way, mimicked an exposure to certain
environmental estrogens [103]. Researchers [104] have shown that TCC at nanomolar
concentrations predisposes rat thymocytes to oxidative stress. The Material Safety Data
Sheet (MSDS) for TCC states that TCC is a hazardous chemical that may cause cancer
and damage to the genetic material [105] due to the possible presence of p-chloroaniline,
a Proposition 65 carcinogen. TCC was shown to strongly augment the overexpression of
aromatase AroB, which is a known target gene for estrogen, in response to treatment with
exogenous estrogen in zebrafish brains. TCC exposure alone could however, stimulate
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AroB expression only slightly [106]. Even though TCC has been postulated to act as an
endocrine receptor, recently, [107] it was shown that TCC mediated activation of
xenobiotic metabolism. Authors in this study [107] used a luciferase based reporter
assay, to demonstrate that TCC activated nuclear xenobiotic receptors: ER-alpha and
constitutive active/androstane receptor (CAR). In the same study, it was also shown that
TCC activated ER-alpha in female rat ovaries leading to induction of Cyp1b1 and also
induced promoter activity of estrogen receptors. Moreover, TCC treatment in mice also
resulted in induction of CAR target gene: UGT1A and Cyp2b10.
Direct dermal exposure to TCC results in transdermal absorption and accumulation in
underlying tissues, including mammary tissues [108.]. A single whole-body shower
using TCC-containing soap results in blood levels as high as ~500 nmol/L within 3 h
[109, 110]. In addition, TCC is resistant to both wastewater chemical and biological
treatments, and agricultural use of TCC-containing bio solids renders TCC into the food
chain, thus increasing human exposure to TCC [101, 111, 112, 113, 114]. Although the
role of TCC in increasing breast cancer risk has been questioned, it has not yet been
addressed. It is imperative to clarify the role of low-dose TCC in sporadic breast cancer
development and to identify effective agents for intervention and this precisely is the
objective of this study.

1.1.3.8 PhIP
2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) (Figure 1.3) is heterocyclic
amine (HCAs) abundantly found in high temperature cooked meats particularly produced
during grilling and barbequeing procedures [115, 116, 117]. Consumption PhIP via such
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meats has been associated with an enhanced risk of breast neoplasia by epidemiological
studies [118, 119]. People who took PhIP at microgram level concentrations via
ingestion, had PhIP available systemically at picomolar and nanomolar concentrations
[117]. Gastric administration of milligram levels of PhIP induced tumors of mammary
gland [117]. Several studies have reported that PhIP is genotoxic to human cells and a
concentration of PhIP as low as 450 nmol/L induced DNA adduct formation [117, 118,
119, 129]. Recently, it was reported that long-term exposure of breast cells to PhIP at
physiologically-achievable, picomolar to low nanomolar doses induced carcinogenesis
and tumorigenicity [121].
In one study, rats were fed PhIP at the rate of 75mg/Kg for 10 continuous days
and this treatment induced proliferation of ductular epithelium, formation of carcinoma in
situ and also mammary gland neoplasia in which high occurrence of H Ras gene
mutations were found [122]. Induction of expression of oncogenic H-Ras in breast
epithelial MCF10A cells confers to MCF 10A cells the capability of invasion which was
accompanied by enhanced expression of metalloproteinases (MMP-2 and MMP- 9) [123]
and ERK (extracellular signal-regulated kinase) pathway activation [124]. Activation of
the ERK pathway causes increased expression of NADPH oxidase-1 (Nox1) and the
enzyme Nox-1 in turn mediates generation of reactive oxygen species (ROS), which
causes increase in cell proliferation, cellular motility, enhanced power of invasion, and
neovascularization [124, 125]. Transient exposure of MCF 10A cells at nanomolar doses
of PhIP caused increased cellular proliferation and activated the ERK pathway [126].
During this activation of ERK pathway, a cascade ensues wherein activation of
downstream members of the ERK pathway members like Raf, Mek, and Erk which
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ultimately generated signals for cell proliferation, cell survival and cellular differentiation
and constitutively activated ERK pathway predisposes cells to malignant transformation
[127]. Repeated exposures to physiologically achievable levels of PhIP in the range of
picomolar to nanomolar concentrations effectively induced progressive carcinogenesis of
human breast epithelial MCF10A cells from a non-cancerous stage to premalignant and
malignant stages in a concentration and exposure dependent way [121]. Step wise
induction of carcinogenesis was accompanied by acquisition of cancer-associated
properties of reduced dependence on growth factors, anchorage-independent growth,
acinar-conformational disruption, increased cellular proliferation, migration, invasion and
carcinogenesis in mouse models. In addition an upregulated H-Ras gene expression, ERK
pathway activation with downstream elevation of Nox-1 expression, and elevated
reactive oxygen species production was noted [121]. Epicatechin gallate and
epigallocatechin gallate, the green tea catechins, were found to suppress PhIP stimulated
cellular carcinogenesis and mammary gland neoplasia [121]. Dipyridamole (DPM), at a
non-cytotoxic physiologically achievable dose of 10nmol/L, effectively blocked breast
cell carcinogenesis induced by cumulative exposures to three different carcinogens
including PhIP [128]. DPM could block H-Ras upregulation, and downstream ERK
pathway activation, reactive oxygen species (ROS) generation, and DNA damage
induced by transient and chronic exposures to PhIP [128]. PhIP at sub nano molar
concentrations has been shown to possess estrogenic activity and was shown to promote
metastatic potential in mammary cancer cell lines and T47D and MCF 7 cells, as seen by
the enhanced ability of the cells to digest and migrate through reconstituted basement
membrane model [129].
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1.2 Precancerous Model of Cancer Progression
Since breast cancer is an important cause of deaths among women especially in the
developed world and more than 85% of breast cancers are sporadic in nature attributable
to long-term exposure to small quantities of environmental carcinogenic agents that
progressively induce non-cancerous cells of breast to acquire pre-malignancy and
gradually to malignancy in a multi-year, multi-step, and multi-path disease process [130,
131, 132, 133, 134]. Hundreds of chemical carcinogens have been identified which have
the ability to intensively induce malignancy in mammary cells [135]. While carcinogens
are capable of inducing cellular malignancy, co-carcinogens are capable of inducing cell
pre-malignancy or enhancing cellular malignancy. Investigations into co-carcinogens, at
low-doses (pico- to nano-molar), capable of chronically inducing cellular pre-malignancy
have been overlooked in past studies of sporadic breast cancer development and early
prevention. In this work I wanted to study whether TCC at physiologically achievable
doses can act as a co-carcinogen to induce premalignant state of breast cancer. Also,
whether, acting as a co-carcinogen, TCC can potentiate or enhance the carcinogenicity
induced by physiologically relevant dosage of PhIP. In previous studies it was
demonstrated that NNK, B[a] P, and PhIP at physiologically achievable doses were
capable of inducing cellular transformation of human breast epithelial cells to
premalignant and malignant stages in breast epithelial cells [42, 121]. So we have
developed a cellular model that tests the potency of various chemicals to induce
premalignant or malignant carcinogenesis which actually mimics everyday exposure to
environmental carcinogens such as daily exposure to tobacco smoke in habitual smokers
[42, 136, 137, 138]. In this approach we use immortalized, non-cancerous human breast
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epithelial MCF10A cells [139]. MCF10A cells were repeatedly subjected to treatment
with carcinogens at picomolar to nanomolar concentrations. This cumulative exposure to
environmental carcinogens induces breast cells to progressively acquire several
identifiable cancer-associated properties simulating chronic exposure of breast cells in
human body to low doses of an environmental carcinogen in daily life. Using this model
we repeatedly exposed immortalized, noncancerous, human breast epithelial MCF10A
cells to TCC and PhIP to nanomolar concentrations and measured the acquisition of
cancer-associated properties and the underlying molecular mechanisms for induction of
cellular carcinogenesis as previously done [42, 121, 140, 141, 142, 143, 144]. Our model
system identifies chemicals capable of inducing premalignant or precancerous and
malignant or cancerous stages in normal cells. The model is advantageous in analyzing
step by step development and progression of carcinogenesis in normal breast epithelial
cells MCF 10A. This model subsequently focusses on identifying preventive compounds
present in our diet that can inhibit multistep carcinogenesis process induced by repeated
exposures to identified co-carcinogens or carcinogens. More importantly, this model
emphasizes the relevance of subduing or preventing the process of carcinogenesis at the
initial “pre-malignant” stage instead of therapeutically targeting transformed cells. The
latter approach can have nonspecific targets and can thus harm the normal body cells too.

1.3 Hallmarks of cancer
The process of neoplasia involves progressive acquisition of certain token characteristics
by normal cells to become tumorigenic and these properties are called hallmarks of
cancer cell [145, 146]. Cancer cells have the ability to grow autonomously and they defy
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normal control mechanisms that are generally put in place to check cell proliferation and
growth. Hanahen and Weignberg, in 2000, initially charted out six cancer cell hallmarks
(Figure 4). They are as follows: ability to activate signaling pathways responsible for
conferring on cells the potential to proliferate abnormally, ability to escape restrictions
imposed on the cell division of normal cells by elements called tumor suppressors, ability
to invade surrounding tissues and metastasize to distant organs, ability to acquire the
potential to replicate with unlimited potential and become immortalized, arrange for
blood supply for the growing mass of tumor i.e. angiogenesis and avoiding apoptosis.
Subsequently in the year 2011, some more hallmarks were added to the original list
which are termed emerging hallmarks and are as follows: ability to alter normal cell
metabolism to accommodate continuous cancerous growth and secondly, the ability to
evade normal host immune response including destruction by cells of the immune
system.
In the present study, assays were used to determine the acquisition of cancer related
characteristics by normal cells after their treatment with co-carcinogen and carcinogen.
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Modified from: Hallmarks of Cancer: The Next Generation 144(5), 2011, 646–67
Hanahan D and Weinberg RA
Figure 1.4. Hallmarks of cancer
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The acquired biological properties that were measured and used as indicators of
acquisition of cancerous properties included reduced dependence on growth factors,
anchorage-independent growth, ability to proliferate abnormally, capability to induce
ROS and activate Erk-Nox cell signaling pathway. The latter two characteristics drive
cells towards abnormal proliferation. Lastly, the potential to migrate and invade
surrounding tissues was also measured. Cancer cells do not respond to signals that
usually regulate cell growth and division. These properties were used as targeted
endpoints to determine the capability of preventive agents to suppress cellular
carcinogenesis.

1.4 Detection of Cancer Progression

1.4.1 Reduced dependence on growth factors:
The cancer cells by definition divide uncontrollably and their proliferation is not
restricted by the amount of growth stimulatory factors present in their surrounding
environment. In addition, growth of cancer cells is not dependent on external stimulatory
cues i.e. those present in the culture media. The cancer cells proliferate without any
checks leading to other cancer cells. So, cancerous cells grow proficiently even in the
absence of growth stimulatory signals that normal cells require from their environment.
Cancer cells do not need stimulation from external signals (in the form of growth factors)
to multiply [145, 147]. Whereas, in the case of normal cells, there is an absolute
requirement for the presence of growth stimulatory factors in the culture media or the cell
surroundings, for the cells to divide and proliferate. In the absence of growth factors, the
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cells die out by the process of apoptosis. So, when the normal cells gain the capability to
survive and proliferate under the conditions which lack adequate growth factors, this
indicates acquisition of a property associated with cancer cells. Hence reduced
dependence on growth factors is a cancer-associated property [42, 121, 140, 141, 142,
143, 144].

1.4.2 Anchorage independent growth
Normal cells require adherence to extracellular matrix for their survival in a multicellular
setting. In the absence of contacts or adhesion to extracellular matrix cells fail to survive
and undergo apoptosis [145]. Unusually enhanced cell survival which causes anchorageindependent cell proliferation is another cancer associated property that can promote
tumorigenic transformation [145, 146]. For instance, primary fibroblastic cell cultures
have an absolute requirement for attachment to external surroundings. So cell lines for
example, NIH-3T3 cannot grow on agar rose or cell suspension. But when these cells
can grow in suspension or on soft agar, they are considered to have acquired the property
of anchorage-independence highly suggestive of acquisition of cancerous traits [148, 149,
150]. Anchorage independence gives the ability to cancer cells to form colonies in soft
agar which can be used to determine progression of cellular carcinogenesis [42, 121, 140,
141, 142, 143, 144].

1.4.3 Migration and Invasion
Normal breast cells grow over basement and do not invade or escape through the
basement membrane. When normal cells become motile and migrate and invade the
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basement followed by invasion into blood stream or lymphatics, they are thought to have
acquired cancer related properties. By being motile and invasive cancer cells can escape
the site of primary tumor formation and via blood or lymphatics reach distant organs and
tissues and colonize there [145, 152].

1.5 Role of ERK Pathway in Cancer
Cellular signal transduction involves conveying messages from extracellular environment
to its intracellular environment through an intricate network of proteins which regulate
numerous cell processes governing cell fates like cell survival, proliferation,
differentiation, migration or apoptosis etc. The cellular signaling mechanism involves
ligand like factors such as, growth factors, steroid hormone, cytokines and G protein
receptor ligands in the extracellular environment impinging on cell surface proteins
called as receptors, and in turn activating them after which ensues a cascade of
downstream cytoplasmic protein kinase activation ultimately leading to conveying of
messages to the nucleus. These protein kinases involved in this signal transduction are
serine threonine kinases and referred to as mitogen activated protein kinases or MAPKs
[153]. In mammals, at present 14 MAPKs have been recognized which have been
allocated to seven groups [154]. Out of these the most studied and conventional MAPKS
include the following: ERK1/2, JNKs, and p38 isoforms [155].
However, the most important and widely studied MAPK in breast cancer is ERK1/2
MAPK pathway [156]. This pathway involves signal transduction via activation of cell
surface receptors mostly tyrosine kinase receptors followed by activation of
Ras/Raf/MEK/ERK cascade ultimately conveying signals via transcription factors which
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regulate expression of a variety of genes [157] (Figure 1.5). Cell surface receptors most
commonly involved in breast cancer include tyrosine kinase receptors of the family:
epidermal growth factor receptors (EGFR). These include EGFR1, EGFRII, EGFR III
and EGFR IV. When appropriate ligand binds to the receptor, dimerization of the
receptor occurs and the receptor subsequently undergoes auto phosphorylation on
tyrosine residues in its cytoplasmic domains. These sites become homing location for
several key adaptor proteins with SH2 or PTB domains e.g. GrB2 which can contact SOS
(son of sevenless) with its SH3 domain and activate it. SOS acts as a guanine nucleotide
exchange factor and helps Ras to exchange its bound GDP for GTP. Ras which now is
able to interact with Raf. Raf is a serine threonine kinase then undergoes conformational
change in response to its interaction with Ras and gets activated. Also, it is postulated
that other kinases can activate it [158]. It then phosphorylates MEK which is a dual
specificity kinase which in turn phosphorylates ERK. ERK upon phosphorylation goes to
nucleus where it can phosphorylate various transcription factors like AP1, ETS, ELK1
etc. which drive transcription of genes important for cell proliferation [158]. The Ras
GTP is reverted back to its inactive Ras GDP form by the hydrolysis of GTP to GDP by
GTPase activating proteins (GAP) [157].
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The Ras Signaling Pathway

Adapted from Yap et al., ChemMedChem. 2011 January 3; 6(1): 38
38–48.Small
Small Molecule
Inhibitors of the ERK Signalling Pathway: Towards Novel Anti
Anti-cancer
cancer Therapeutics
Figure 1.5. EGFR-Ras-Erk
Erk Pathway
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The importance of MAPK activation in breast cancer tissues was first demonstrated by
Sivaraman et al. [159]. In their study they studied MAPK pathway activation in tissues
obtained from primary breast cancer patients and compared these with benign breast
tissues using western immunoblotting techniques and substrate based MAPK enzyme
assays. They found that all tissues from breast cancer patients showed marked activation
of MAPK signaling.
Some researchers [160] prepared extracts from 23 human breast cancer tissues and
normal surrounding areas from the same tissue. Then using immune-precipitation assay
and substrate enzyme assay they found that there was up to 2.5 times greater activity of
ERK1 and ERK 2 in 50 percent of the examined breast cancer samples. Also, they
showed increased MEK protein expression and activation for the first time in breast
cancer tissues. In another study by Muller et al., all of the 131 breast cancers examined
had significantly higher activation of MAPK protein expression and kinase activity as
compared to the 18 normal tissues surrounding the breast cancer tissues analyzed [161].
Even though MAPK protein expression correlated with MAPK activity in only a fraction
of the tissues analyzed. Tissues obtained from node positive cancer patients showed
higher MAPK activity as compared to tumor tissues from the node negative individuals.
Moreover, patients with a replase of the disease had higher MAPK activity as compared
with patients with no replase. So, MAPK activation was suggested to be a potential
marker for a relapse free survival. Vonlinting et al., demonstrated that in the presence of
overexpression of EGFR and HER2 receptors, Ras was found to be overly activated in 11
out of 20 primary breast cancer tissues examined as compared to non-tumor samples
indicating that in the presence of ligands and overexpression of their cognate receptors
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Ras upregulation may be the driving force for an activated MAPK pathway, hence
suggesting a possible mechanism for upregulation of MAPK in breast cancer specimen
[162]. In an attempt to clarify the mechanisms behind upregulated MAPK activity and
protein expression in tumor tissues, some people [163], showed that in the primary mouse
mammary cultures, presence of epidermal growth factor caused activation of MAPK.
Hence, current research clearly shows the importance of activated ERK Pathway in breast
cancer [156]. Studies have also shown that ERK pathway activation can result in
response to an exposure to environmental carcinogens at a high concentration [164].
Recent research has also shown that long term exposure to low dose of environmental
carcinogens such as those present in diet, tobacco smoke etc. can induce carcinogenesis
in normal breast epithelial cells [42, 121, 141], which is accompanied by upregulation of
MAPK pathway. Also, there exists a need to assess the potential hazards of a long term
exposure to various chemicals that humans are exposed to in their day today life, on the
basis of their ability to cause upregulation of MAPK pathway in normal cells especially
those of breast tissues.

1.6 Role of Reactive Oxygen Species in Cancer
Reactive oxygen species are a class of reactive chemicals derived from oxygen and
generated during mitochondrial respiration and oxidation-reduction enzymatic reactions
in the cytoplasm. Main types of ROS include: superoxide anion; hydrogen peroxide;
hydroxyl radical; hydroxyl ion; and nitric oxide [165, 166]. ROS producing compounds
have the capability to cause or modulate progressive carcinogenesis induction [167]. As
is evident by recent research, reactive oxygen species plays a prominent role in
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tumorigenesis in many organs like in case of prostate cancer [168, 169]. Various sources
of cellular ROS include mitochondria, peroxisomes and cytochromes. Exogenous
sources of ROS generation are exposure to UV radiation, inflammatory processes and
infectious agents. ROS thus generated introduces tremendous oxidative stress on the
cellular machinery leading to damage to DNA, RNA and lipid components of the cell,
protein denaturation, genomic instability and alteration in gene expression profile.
Cellular enzyme Nox (NADPH oxidase) is also responsible for generation of ROS.
Environmental agents capable of generating ROS include benzopyene, PhIP, phorbol
ester, heterocyclic amines like PhIP, chlorinated compounds, inorganic metals like nickel
and chromium etc., which can induce oxidative stress and consequent damage to cellular
machinery, as has been shown in many studies [167]. Studies have documented that nongenotoxic chemicals may be able to induce carcinogenesis by virtue of their ability to
induce oxidative stress. Environmental agents capable of inflicting both acute and
chronic oxidative insult on the cell have the potential to cause cancer [170]. Most
frequently encountered ROS induced DNA and RNA lesions include 8-hydoxyguanine
and 8-hydroxydeoxyguanine [171]. Moreover, 8-hydoxyguanine and 8hydroxydeoxyguanine have been touted as the most detrimental in forming DNA adducts
and mutations [172]. Studies have described formation of more than 100 different types
of adducts affecting purine or pyrimidine rings and DNA backbone structures [173, 174,
175, 176]. It is believed that oxidative damage to DNA machinery in man occurs at an
alarming rate of 104 lesions/ cell/ day [173, 177]. ROS can not only be produced by
exposure to high dosage of carcinogens [178], but also, recent studies have shown that
low dose chronic exposure to environmental carcinogens, especially at their
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physiologically relevant concentrations, can cause significant ROS production leading to
DNA damage and breast cellular carcinogenesis [42, 121]. Role of Erk –Nox pathway in
generating ROS and beast cell carcinogenesis has been shown in some studies but needs
to be further validated. Similarly, there is a need to see if low level of ROS generated in
response to exposure to physiologically achievable doses of chemicals, with which we
come in contact on a day to day basis, would be able to induce breast cellular
carcinogenesis. Furthermore, it needs to be determined whether TCC can induce ROS in
breast cells.

1.7 NADPH Oxidase-1
Reactive oxygen species is generated by action of family of enzymes called as NADPH
oxidases [nicotinamide adenine dinucleotide phosphate (NADPH) oxidase or Nox family
oxidases]. ROS produced by NOX family of enzymes can in turn affect several cellular
functions like migration, invasion, proliferation etc. Currently there are seven well known
isoforms of NOX family Nox1 to Nox 5 and DUOX 1-2 [179]. A divergent variety of
cells in the body are known to express Nox-1 like: epithelial cells, retina, smooth muscle,
bone cells, endothelium and others[180, 181, 182, 183, 184, 185]. Over expression of
Nox1 was found to cause cell growth, proliferation, cell transformation and
tumorigenicity in nude mouse models [186]. Over expression of Nox1 has been reported
in cases of colon cancer [187, 188]. Nox -1 levels were found to be elevated in breast
cells chronically exposed to dietary carcinogen PhIP [121]. Nox-1 were found to be over
expressed in more than 85 percent of breast and 70 percent ovarian tumors and its
expression levels were tightly regulated by mitochondria. Moreover, deregulation of
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mitochondrial control over nox-1functioning contributed to ovarian and breast tumors.
[189].

1.8 Cancer preventive substances in diet
Due to difference in lifestyle, climatic and environmental conditions including diet in
different regions of the world, wide variations in incidence of cancer and cancer related
deaths are noted across different geographical regions of the world [190]. Dynamic
studies and migrant studies done by various authors have compared cancer rates among
native and migrant populations in host country and have linked different rates of cancer
among these two populations to differences in dietary, environmental and other lifestyle
factors [191, 192]. Diet may contribute to cancer related deaths [193]. A large number
of studies have studied the link between intake of fruits and vegetable to occurrence of
cancers of the various organs, in the body including breast cancer [194, 195]. Naturally
occurring agents such as flavonoids, polyphenols, etc. present readily in fruits,
vegetables, and spices’ owing to their ability to suppress cancers, have been in sharp
focus of both general public as well as the scientists world over and, the scientific
evidence that supports their suspected anti-cancer activities is being explored in the
current ongoing research. Recent research has made it clear that the diet plays a pivotal
role in the arena of cancer prevention [196].
Various compounds with anti-tumor activity have been identified in different
kinds of fruits and vegetables [197]. Dithiolthiones and isothiocyanates in high quantities
are present in cruciferous vegetables and their anti-tumor activity is due to their ability to
enhance the activity of enzymes involved in cleansing the metabolically harmful forms of
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carcinogens and xenobiotic substances [198]. The diallyl sulfide and allyl methyl
trisulfide present in onions and leeks are also involved in inducing enzymatic
detoxification machinery [199]. Genistin, an isoflavonoid extracted from soyabeans,
could inhibit enzyme tyrosine kinase activity thus impeding signals downstream of cell
surface receptors known to be highly upregulated in tumor cells [200]. Compounds with
anti-oxidant activity, such as carotenoids and xanthophylls, are reported to be present in
leaves of green vegetables [201]. Beta-carotene present in colored fruits and vegetables
like mango, carrots pumpkin and papaya, can protect a cell against oxidative damage
induced by reactive oxygen species [202]. Polyphenolic anti-oxidant flavonoids like
quercetin, which are present in fruits, vegetables and tea, can facilitate efflux of
intracellular carcinogens and also activate the cellular enzymatic machinery responsible
for detoxifying toxins [203, 204, 205]. Fiber rich foods such as vegetables and fruits
have preventive activity against colon cancer [206]. Intake of a healthful diet consisting
of large amounts of fruits and vegetables can help thwart cancer development.
Polyphenolic compounds present in green tea have shown promising anti-cancer activity
[207, 208, 209, 2010]. Green tea has preventive effect against various types of cancer
and was shown to be effect in preventing skin cancer in animal models, angiogenesis,
tumor growth and its invasion and metastasis to distant organs [211, 212, 213, 214, 215].
Epicatechin gallate (ECG) a flavonoid present in green tea extract can interfere with the
process of carcinogenesis in a variety of ways including activation of cellular
detoxification machinery, inhibition of enzyme responsible for producing active form of
carcinogen like cyp1A1, blocking inflammation and inhibiting metastasis [216, 217, 218,
219, 220]. Epigallocatechin (EGC) also has numerous preventive properties [221, 222].
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Epigallocatechin-3-gallate (EGCG), another polyphenolic compound present in green tea,
has been shown to possess cancer preventive activity which is attributed to its antioxidant
activity [122]. Hence, by counteracting reactive oxygen species produced by a variety of
different carcinogens, EGCG was shown to prevent chronic breast cell carcinogenesis
[42, 121]. It has been used as a therapeutic agent in various types of cancers like cervical
and bladder cancers. Grape seed extract (GPSE) is enriched in proanthocyanidins, which
possesses anti-oxidant activities that were shown in both cell culture studies and animal
model studies to be responsible for its anti-tumor activities [223, 224, 225, 226]. In
addition, GPSE prevented mammary carcinogenesis induced by carcinogen
dimethylbenz[a]anthracene (DMBA). Grape seed proanthocyanidins were found to
prevent chronic breast cell carcinogenesis induced by NNK ans B[a]P [141].
This study focusses on the significance of naturally occurring compounds
including those that can be taken easily through daily diet like curcumin, and others like
Mimosine and Ergosterol, in prevention of sporadic breast cancer and more specifically
chronic breast cell carcinogenesis.

1.8.1 Curcumin
Indian yellow herb turmeric derived from Curcuma longa, has been commonly used since
ancient times in Asian food diets as a yellow coloring powder and spice [227, 228, 229].
Turmeric mainly contains the following three curcuminoids: diferuloylmethane;
demethoxycurcumin, and bisdemethoxycurcumin, along with volatile oils (tumerone,
atlantone, and zingiberone), sugars, proteins, and resins [230]. Curcumin, is the major
phenolic curcuminoid in the extracts made from turmeric and the one which is
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responsible for the yellow color of turmeric. Moreover, since ages curcumin has been
used in the traditional Indian medicine to treat cancer, rheumatic disorders, inflammation,
gastrointestinal and ocular diseases [229, 231, 230]. Curcumin has been shown to inhibit
proliferation of triple negative MDA-MB-231 breast cancer cells by inhibiting EGFR
signaling pathway with down regulation of pERK1/2 and pEGFR protein expression
[232]. MDA-MB-231 cells showed slower proliferation rates after treatment with
curcumin. In addition, curcumin treatment also caused these cells to undergo cell cycle
arrest at the G2/M stage and subsequently apoptosis. Also, cell cycle inhibitor, p21, was
found to be over expressed along with an elevation of bax to bcl2 ratio in these cells
[233]. It has been shown that curcumin is able to inhibit growth and metastasis of breast
cancer cells in vitro [234, 235] and in vivo [235]. Curcumin was able to inhibit the in
vitro migration in MDA-MB-231 cells through down-regulating the protein expression of
NF-kappaB [234]. Curcumin has been shown to limit the metastatic potential of triple
negative breast cancer cell lines [233]. In clinical trials, curcumin treatment is being
applied to a number of patients with breast cancer, rheumatoid arthritis, Alzheimer's
disease, colorectal cancer, psoriatic, etc. Several of these clinical trials have reported the
curcumin treatment to be safe and effective [230, 236, 237]. Curcumin can target and
affect expression of a variety of proteins including those involved in cell survival,
proliferation, migration, invasion, and angiogenesis. Thus, there exists an extensive
evidence substantiating curcumin’s capability as an anticancer agent in a wide variety of
tumors and, it has been shown to inhibit the proliferation of tumor cells in vitro, can
suppress carcinogenesis in rodents, and has been shown to decrease growth of human
tumors in both orthotopic and xenograft tumor models [237]. Curcumin has been shown
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to suppress mutagenic effects induced by a wide variety of carcinogens [238, 239, 240].
Curcumin was shown to inhibit benzo[a]pyerene-induced tumorigenesis in fore stomach
in mouse models [238, 241], genotoxicity induced by cooked food heterocyclic amines in
Salmonella typhimurium strains [240], and bio activation of benzo[a]pyerene diol in oral
squamous carcinoma cells [242]. However, the activity of curcumin in prevention of
sporadic breast cancer has not been investigated. Moreover, despite its efficacy and
potential as a therapeutic anticancer agent, it is yet to be approved as a therapeutic agent
because of its poor bioavailability [243, 244, 245]. But the use of various adjuvants like
piperine which inhibits hepatic and intestinal glucuridation machinery, have been shown
to dramatically improve bioavailablity of curcumin [245, 246]. Similarly, nanoparticle
based delivery systems [247] and liposomal drug delivery subsystem has been shown to
be promising agents in improving bioavailability of curcumin. Liposomal curcumin was
shown to inhibit pancreatic carcinoma growth and angiogenesis in in vivo tumor models
[248]. Curcumin structural analogues have also been developed to enhance curcumin
bioavailability. Curcumin analogues which have no β-diketone moiety such as monocarbonyl analogs could enhance its bioavailability and stability [249].

1.8.2 Ergosterol
Ergosterol forms a major constituent of fungal cell membrane. Its structure is shown in
Figure 1.6. It plays a hormone like role in fungal cells and stimulates growth of fungus.
The antitumor activity of ergosterol might be due to direct inhibition of angiogenesis
induced by solid tumors [250]. Ergosterol extracted from Japanese edible mushroom
Hypsizigus marmoreus showed inhibitory activity against 12-O-tetradecanoylphorbol-13-
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acetate (TPA) induced ear inflammation and tumor promotion in mice in a two stage
experimental carcinogenesis study and hence could be used as a potential anticancer
agent [251]. Ergosterol Peroxide (EP) is found in lichens and mushrooms and it
possesses immunosuppressive anti-viral, anti-inflammatory and anti-tumor activities
[252, 253, 254, 255, 256]. Ergosterol peroxide present in oil rich fraction isolated from
Ganoderma lucidum showed promising results in overcoming the drug-resistance of
tumor cells attributed to the expression of miR-378 [257]. Ergosterol peroxide exhibits
anticancer activity in multiple myeloma U266 cells. It was shown to be an anti-cancer
agent which targets JAK2/STAT3 signaling pathway and inhibits angiogenesis against
multiple myeloma cells. However, there is paucity of knowledge regarding the ability of
ergosterol to act as a preventive agent in cases of breast cancer.

1.8.3 Mimosine

Mimosine or leucenol is an alkaloid, β-3-hydroxy-4 pyridone amino acid which is
chemically very similar to tyrosine. Its structure is shown in Figure 1.6. It was initially
isolated from Mimosa pudica and is found to occur in some members of genus Mimosa
and all members of the related genus Leucaena [258].
It is a non-protein, plant origin free amino acid that is toxic to non-ruminants and unadapted ruminants. Mimosine is an iron chelator and that inhibits DNA synthesis and
mammalian cell proliferation by blocking cell cycle at the late G1 phase [259, 260, 261,
262]. It has been shown to inhibit cell proliferation in prostate carcinoma cells [263].
Mimosine was specifically shown to inhibit cyclin D1 expression [264], and upregulate
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the protein expression levels of p27 [265]. In vivo studies have also demonstrated that it
has an anticancer effect on human lung cancer xenografts [266]. Studies have been
conducted that gave an evidence of the ability of mimosine to suppress the growth of
human pancreatic cancer xenografts that were subcutaneously transplanted in nude mice
and a flow cytometric analysis of the tumor cells yielded a significantly increased sub-G1
fraction indicating occurrence of apoptosis [267]. Since its role in inhibiting cancer of
breast cells has not been studied, this study was done to determine if Mimosine could
inhibit breast cellular carcinogenesis.
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Figure 1.6 Chemical structures of preventive agents
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1.9 Hypothesis and Objective
I have already discussed that more than 85% of breast cancers are sporadic and
attributable to long-term exposure to small quantities of environmental carcinogenic
agents that progressively induce non-cancerous cells to pre-malignancy to malignancy in
a multi-year, multi-step, and multi-path disease process. Carcinogens are capable of
inducing cellular malignancy, and co-carcinogens are capable of inducing cell premalignancy or enhancing cellular malignancy. Very few studies have been done to
investigate the potential of co-carcinogens to induce the state of cellular pre-malignancy
or enhance carcinogenicity of other known carcinogens. There are a plethora of
chemicals that humans are exposed to daily, however, the effects of their exposure on
human health are largely unknown. Many such chemicals possess the hitherto unknown
capacity to act as mitogens, induce cellular damage and capability to act as cocarcinogens in initiation and progression of various kinds of cancers including breast
cancer. Hence, there exists a need to characterize such chemicals on the basis of their
potency to induce premalignant or malignant breast cell carcinogenesis. Moreover, since
exposure to some of these potential carcinogens cannot be avoided, there is an imminent
need to search for compounds occurring in nature, which have the preventive activity to
thwart the process of carcinogenesis initiated by exposure to carcinogens or cocarcinogens. Furthermore, early prevention of breast cancer obviates the need for
therapeutics and its subsequent complications. Triclocarban is a chemical to which body
is exposed via a number of ways everyday viz. through shower, hand washes, antiseptics,
deodorants etc. Though, recently there has been a lot of focused research to determine
the effects of TCC on human health, yet the potential of TCC to act as a co-carcinogen
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has not been addressed so far. Cooked meat carcinogen PhIP has been shown to cause
breast carcinogenesis. But whether certain co-carcinogens can enhance the
carcinogenicity of PhIP when body is exposed to them simultaneously, this has not been
verified till date. So, the cumulative impact of a bodily co-exposure of PhIP and TCC
through different unavoidable sources on breast cells has not been addressed before.
Also, there is a relative lack of work seeking to uncover the potential of naturally
occurring preventive agents that can counteract the role of co-carcinogens and
carcinogens and block progression of premalignant breast cell carcinogenesis. Hence to
address the above needs this study was undertaken with the following central hypothesis:
Long-term exposure to TCC can cause breast cell carcinogenesis and co-exposure to TCC
and PhIP can enhance PhIP-induced breast cell carcinogenesis
Then working towards the central hypothesis the study was divided into four broad
objectives:
 To determine if chronic exposure to physiologically achievable doses of TCC can
cause breast epithelial cells to acquire the cancer-associated properties.
 To study potential of curcumin in intervention of TCC-induced breast cell
carcinogenesis.
 To determine if TCC can enhance PhIP-induced breast cell carcinogenesis.
 To determine whether mimosine and ergosterol can block breast cell
carcinogenesis induced by co-treatment of TCC and PhIP.
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TABLE 1: MICOARRAY CLASSIFICATION OF BREAST CANCER (MODIFIED
FROM Krishnamurthy et al., 2012)
Subtypes

ER/PR /Her2

Other Immuno-

Status

Histochemical

Cell Of Origin

Other
Characters

Features
Luminal A

ER or PR +ve or

keratin 8/18 +ve

both Her2 -ve

luminal epithelial

Best prognosis

cell

Higher survival
rate

Luminal B

ER or PR +ve or

keratin 8/18 +ve

both, Her2 +ve

luminal epithelial

Higher tumor

cell

grade, Poorer
prognosis

Basal Like

Her 2+

ER/PR –ve,

keratin 5/6/17 +ve

Basal/myoepithelial/

Her2 +ve/-ve

EGFR +ve

bipotentl progenitor

ER/PR –ve,

-

Late luminal

20-25%, Poorer

progenitor

grade and

Her2 +ve

15%

prognosis
Normal

Tumors that

Breast Like

don’t fill any of

Claudin Low

-

Luminal epithelial

6-10%, associated

cell

with

the other

fibroadenomas,

categories

Good prognosis

All –ve

mesenchymal markers

Stem cells

Typically triple –
ve 5-10% of all
tumors

ER: Estrogen resceptor, PR: Progestron receptor, Her2; Human epidermal growth factor
receptor2
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Table 2:List of risk factors
Hereditary and non-modifiable risk

Environmental and modifiable risk factors

factors
Age

Physical inactivity

Gender

Alcohol

Genetic factors (BRCA1 and BRCA2

Smoking

gene mutation)
Race

Unhealthy diet

Menstrual and reproductive factors

Exposure to ionizing radiation

Proliferative breast conditions

Hormonal replacement therapy
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Chapter 2

Induction of Human Breast Cell Carcinogenesis by Triclocarban
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Research described in this chapter is slightly modified version of an article that has been
submitted to Molecular Carcinogenesis in April, 2013
Induction of Human Breast Cell Carcinogenesis by Triclocarban by
Shilpa Sood, Shambhunath Choudhary, and Hwa-Chain Robert Wang

In this paper “our” and “we” refers to me and co-authors. My contribution in the
paper includes the following:
(1) Selection of the topic (2) Compiling and interpretation of the literature (3)
Designing experiments (4) understanding the literature and interpretation of the
results (5) providing comprehensive structure to the paper (6) Preparation of the
graphs and figures (7) Writing and editing
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2.1 Abstract
More than 85% of breast cancers are sporadic and attributable to long-term
exposure to environmental carcinogens and co-carcinogens. To identify co-carcinogens
with abilities to induce cellular pre-malignancy, we studied the activity of triclocarban
(TCC), an antimicrobial agent commonly used in household and personal care products.
Here, we demonstrated, for the first time, that chronic exposure to TCC at
physiologically-achievable nanomolar concentrations resulted in progressive
carcinogenesis of human breast cells from non-cancerous to pre-malignant. Premalignant carcinogenesis was measured by increasingly-acquired cancer-associated
properties of reduced dependence on growth factors, anchorage-independent growth and
increased cell proliferation, without acquisition of cellular tumorigenicity. Long-term
TCC exposure also induced constitutive activation of the Erk-Nox pathway and increases
of reactive oxygen species (ROS) in cells. A single TCC exposure induced transient
induction of the Erk-Nox pathway, ROS elevation, increased cell proliferation, and DNA
damage in not only non-cancerous breast cells but also breast and bladder cancer cells.
Using these constitutively- and transiently-induced changes as endpoints, we revealed
that non-cytotoxic curcumin, a component of turmeric extracted from the Indian herb
Curcuma longa, was effective in intervention of TCC-induced cellular pre-malignancy.
Our results lead us to suggest that the co-carcinogenic potential of TCC should be
seriously considered in epidemiological studies to reveal the significance of TCC in the
development of sporadic breast cancer. Using TCC-induced transient and constitutive
endpoints as targets will likely help identify non-cytotoxic preventive agents, such as
curcumin, effective in suppressing TCC-induced cellular pre-malignancy.
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2.2 Introduction
Breast cancer is the most common cancer and the second leading cause of cancer
deaths among women in northern America and Europe [1]. More than 85% of breast
cancers are sporadic and attributable to long-term exposure to small quantities of
environmental carcinogenic agents that progressively induce non-cancerous cells to premalignancy to malignancy in a multi-year, multi-step, and multi-path disease process [2–
5]. Over 200 chemical mammary carcinogens have been identified by measuring their
ability to intensively induce malignant cells or tissues [6]. While carcinogens are capable
of inducing cellular malignancy, co-carcinogens are capable of inducing cell premalignancy or enhancing cellular malignancy. Investigations into co-carcinogens, at
low-doses (pico- to nano-molar), capable of chronically inducing cellular pre-malignancy
have been overlooked in past studies of sporadic breast cancer development and early
prevention.
One potential co-carcinogen, triclocarban (TCC, or 3,4,4'-trichlorocarbanilide) is
a lipophilic, antimicrobial compound widely used in household and personal care
products, such as disinfectants, soaps, deodorants, detergents, and wipes, etc [7]. TCC
exhibits endocrine-disrupting activity to induce estradiol-dependent activation of estrogen
receptor (ER)-responsive gene expression but alone lacks agonistic activity [8,9]. Direct
dermal exposure to TCC results in transdermal absorption and accumulation in
underlying tissues, including mammary tissues [10]. More specifically, a single wholebody shower using TCC-containing soap results in blood levels as high as ~500 nmol/L
within 3 h [11,12]. In addition, TCC is resistant to both wastewater chemical and
biological treatments, and agricultural use of TCC-containing biosolids renders TCC into
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the food chain, thus increasing human exposure to TCC [7,13–15]. Although the role of
TCC in increasing breast cancer risk has been questioned, it has not yet been addressed.
It is imperative to clarify the role of low-dose TCC in sporadic breast cancer development
and to identify effective agents for intervention.
One possible hindrance for such sporadic breast cancer development is curcumin,
the major phenolic compound in turmeric extracts. Curcumin has been used in Asian
countries for hundred years to treat various diseases, including gastrointestinal, retinal,
and rheumatic disorders, as well as inflammation and cancer [16–20]. It has been shown
that curcumin is able to inhibit growth and metastasis of breast cancer cells both in vitro
and in vivo [21–23]. Curcumin has also been shown to inhibit stomach tumors induced
by benzo[a]pyerene (B[a]P) in mice [24,25], genotoxicity induced by heterocyclic amines
in Salmonella typhimurium [26], and bioactivation of B[a]P-diol in oral squamous
carcinoma cells [27]. However, the activity of curcumin in prevention of sporadic breast
cancer has not been addressed.
We have developed a cellular model to identify carcinogenic agents, at
physiologically-achievable levels, capable of chronically inducing human breast
epithelial cell carcinogenesis [28–33]. We revealed that and cellular, biochemical, and
molecular changes transiently induced by single exposure to carcinogenic agents, and
changes constitutively induced by cumulative exposures play essential roles in induction
of cellular carcinogenesis and maintenance of acquired cancer-associated properties,
respectively [28–33]. We then used these transient and constitutive changes/endpoints as
targets to identify non-cytotoxic agents, such as green tea catechins and grape seed
extract, effective in intervention of cellular carcinogenesis [29–36]. In this
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communication, we used our model system, for the first time, to reveal the ability of
TCC, at nanomolar levels, to induce breast cell pre-malignancy. We also studied the
activity of curcumin, at non-cytotoxic levels, effective in intervention of TCC-induced
cellular carcinogenesis.
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2.3 Materials and methods
2.3.1 Cell Cultures and Reagents
MCF10A (American Type Culture Collection [ATCC], Rockville, MD) and
derived cell lines were maintained in complete (CM) medium (1:1 mixture of DMEM
and HAM's F12, supplemented with 100 ng/mL cholera enterotoxin, 10 µg/mL insulin,
0.5 µg/mL hydrocortisol, 20 ng/mL epidermal growth factor, and 5% horse serum) [28–
36]. Human breast cancer MCF7 and urinary bladder carcinoma J82 cells (ATCC) were
maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum [33].
All cultures were maintained in medium supplemented with 100 U/mL penicillin and 100
µg/mL streptomycin in 5% CO2 at 37°C. Stock aqueous solutions of TCC (SigmaAldrich, St. Louis, MO), chloromethyl-dichlorodihydrofluorescein-diacetate (CMH2DCF-DA) (Invitrogen, Carlsbad, CA), U0126 (Cell Signaling, Beverly, MA), and
curcumin (MP Biomedicals, Solon, Ohio) were prepared in DMSO and diluted in culture
medium. Stock aqueous solutions of N-acetyl-L-cysteine (NAC) (Alexis, San Diego,
CA) were prepared in H2O and diluted in culture medium for assays.

2.3.2 Chronic Induction of Cellular Carcinogenesis
Twenty-four h after each subculturing, MCF10A cells were exposed to TCC for
48 h, as one cycle of exposure for 10 to 20 cycles; cultures were subcultured every 3 d
[28–33]. After exposures to TCC, cells were assayed to detect acquired cancerassociated properties.
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2.3.3 Reduced dependence on growth factors
Five × 103 cells were seeded in 60-mm culture dishes and maintained in lowmitogen (LM) medium containing reduced total serum and mitogenic additives to 2% of
the concentration formulated in CM medium. Cell colonies (≥ 0.5 mm diameter) grown
in LM medium were counted microscopically [29–33].

2.3.4 Anchorage-independent Growth
Five x 103 cells were mixed with soft-agar consisting of 0.4% SeaPlaque agarose
(Sigma-Aldrich) in a mixture (1:1) of CM medium with 3 d conditioned medium
prepared from MCF10A cultures, plated on top of the 2% SeaPlaque agarose base layer
in a 60-mm culture dish, and maintained for 20 d to develop cell clones. Cell colonies (≥
0.1 mm diameter) grown in soft-agar were counted microscopically [29–33].

2.3.5 Cell Viability Assay
A Methyl Thiazolyl Tetrazolium (MTT) assay kit (ATCC) was used to measure
cell survivability in cultures. Five x 103 cells were seeded into each well of 96-well
culture plates for 24 h. After indicated treatments, cells were incubated with MTT
Reagent for 4 h, followed by incubation with detergent reagent for 24 h. Reduced MTT
reagent in cultures was quantified with an ELISA reader (Bio-Tek, Winooski, VT)
[37,38].
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2.3.6 Cell Proliferation
Cell proliferation was determined by of 5-bromo-2’-deoxyuridine (BrdU)
incorporation into cellular DNA using the BrdU cell proliferation ELISA kit (Roche,
Indianapolis, IN). Five x 103 cells were seeded into each well of 96-well culture plates
for 24 h. After treatment, cells were labeled with BrdU for 12 h, fixed, incubated with
peroxidase-conjugated BrdU-specific antibodies, and stained with peroxidase substrate.
Quantification of BrdU-labeled cells was determined with an ELISA reader (Bio-Tek)
[37–39].

2.3.7 Intracellular ROS
As performed previously [32–36,40], cells were incubated with 5 µmol/L CMH2DCF-DA for 1 h to detect ROS level by flow cytometry; the mean fluorescence
intensity of DCF was quantified using Multicycle software (Phoenix).

2.3.8 DNA Damage
DNA damage was measured by a comet assay [33,41]. Cells were mixed with 1%
low-melting agarose and placed on agarose-coated slides. Slides were then immersed in
lysis solution (1.2 mol/L NaCl, 100 mmol/L Na2EDTA, 1% Triton X-100, and 0.3
nmol/L NaOH, pH 13) at 25°C for 1 h and rinsed three times with alkaline buffer (2
mmol/L Na2EDTA and 300 mmol/L NaOH) for 20 min each. After electrophoresis in the
same alkaline buffer at 20V for 30 min, slides were stained with 2.5 µg/mL of propidium
iodide for 20 min and examined with a Zeiss fluorescence microscope (Thornwood, NY)
equipped with an excitation filter of 546 nm and barrier filter of 590 nm. Fifty nuclei per
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slide were scored for tail moment (% of DNA in the tail × tail length) using CometScore
software (Tritek, USA).

2.3.9 Western Immunoblotting
Equal amounts of cellular proteins were resolved by electrophoresis in 10% SDSpolyacrylamide gels and transferred to nitrocellulose filters for immunoblotting [42–44].
Specific antibodies were used to detect H-Ras, phosphorylated Mek (p-Mek), Mek,
phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, Nox-1, and β-Actin (Santa Cruz
Biotechnology, Santa Cruz, CA). Antigen-antibody complexes on filters were detected
by the Supersignal chemiluminescence kit (Pierce, Rockford, IL).

2.3.10 Statistical Analysis
The Student t test was used to analyze statistical significance, indicated by * P <
0.05, ** P < 0.01, *** P < 0.001; a P value of ≤ 0.05 was considered significant.

2.4 Results & Discussion

2.4.1 Induction of Breast Cell Carcinogenesis by TCC
To investigate the ability of TCC to induce breast cell carcinogenesis, we
repeatedly exposed MCF10A cells to TCC at various concentrations for 10 and 20 cycles.
Normal epithelial cells require growth factors to grow and survive, and cell adhesion to
extracellular matrix is essential for survival in a multi-cellular environment; in contrast,
cancerous cells acquire the abilities of a reduced dependence on growth factors and an
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independence from cell adhesion to matrix (anchorage-independent growth) to survive
[45,46]. We used these two cancer-associated properties as constitutive endpoints to
measure the progress of cellular carcinogenesis induced by cumulative exposures to
various carcinogenic agents [32,33]. As shown in Figure 2.1A and 2.1B, higher numbers
of survived colonies, which acquired both cancer-associated properties, remained in
cultures exposed to TCC at higher concentrations than in cultures exposed to lower
concentrations (1000 > 500 > 200 nmol/L), and higher numbers of colonies survived in
cultures exposed to TCC for 20 cycles than in cultures exposed for 10 cycles. These
results indicate that cumulative exposures of MCF10A cells to TCC resulted in
progressively-increased acquisition of these two cancer-associated properties/constitutive
endpoints in a dose- and exposure-dependent manner.
Our previous studies [32,33] revealed that the Erk-Nox pathway, as a constitutive
biochemical endpoint, is involved in maintaining acquired cancer-associated properties of
pre-malignant and malignant breast cells induced by chronic exposure to carcinogenic
agents, including B[a]P, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and 2amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Investigating signaling
pathways involved in TCC-induced cellular carcinogenesis, we detected that As shown in
Figure 1C, chronic exposure to TCC also resulted in constitutive activation of the ErkNox pathway, indexed by increased phosphorylation of Erk1/2 and increased level of
Nox-1 (Figure 2.1C). The level of induced Erk-Nox pathway (Figure 2.1C) was in
concert with the degree of acquired cancer-associated properties (2.1A & B).
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Legend for Figure 2.1. Dose- and exposure-dependent induction of carcinogenesis
by TCC. MCF10A cells were repeatedly exposed to DMSO (0) or 200, 500, or 1000
nmol/L (nM) TCC for 10 and 20 cycles. (A) To determine acquisition of the cancerassociated property of reduced dependence on growth factors (RDGF), cells were
maintained in LM medium. (B) To determine acquisition of the cancer-associated
property of anchorage-independent growth (AIG), cells were seeded in soft-agar. Cell
colonies were counted microscopically. Columns, mean of triplicates; bars, SD.
Statistical significance is indicated by ** P < 0.01, *** P < 0.001. (C) Cell lysates
isolated from cultures exposed to TCC for 20 cycles were analyzed by immunoblotting
using specific antibodies to detect levels of phosphorylated Erk1/2 (p-Erk1/2), Erk1/2,
and Nox-1, with β-Actin as a control; these levels were quantified by densitometry. The
level of specific phosphorylation of Erk1/2 (p-Erk/Erk) was calculated by normalizing
the level of p-Erk1/2 with the level of Erk1/2, the level set in control cells (0 nM TCC) as
1 (X, arbitrary unit). The level of Nox-1 (Nox/Actin) was calculated by normalizing with
the level of β-Actin, the level set in control cells as 1 (X, arbitrary unit). All results are
representative of three independent experiments.
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Figure 2.1. Dose- and exposure-dependent induction of carcinogenesis by TCC
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These results are consistent with our published findings of constitutive endpoints induced
by B[a]P, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and/or 2-amino-1methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in breast cell carcinogenesis [32,33]; thus,
the cancer-associated properties of reduced dependence on growth factors and anchorageindependent growth can also be used as constitutive cellular endpoints in the
measurement of TCC’s ability to induce cellular carcinogenesis, and the Erk-Nox
pathway can be used as a constitutive biochemical endpoint to detect TCC-induced
cellular carcinogenesis.

2.4.2 Transient Endpoints Induced by TCC
Our previous studies revealed that a single exposure of MCF10A cells to B[a]P,
NNK, or PhIP induces transient endpoints, including Erk-Nox pathway activation, ROS
elevation, increased cell proliferation, and DNA damage, which play essential roles in
initiation of carcinogenesis in each exposure, accounting for the mechanisms of these
agents in chronic induction of carcinogenesis [32,33]. To detect transient endpoints
induced by TCC, we exposed MCF10A cells to 200 nmol/L TCC for 48 h. Because
studies showed that a single whole-body shower using TCC-containing soap frequently
results in blood levels at ~200 nmol/L [11,12], we chose to use the physiologicallyachievable level of 200 nmol/L TCC to study its activity and mechanisms in induction of
cellular carcinogenesis.
As shown in Figure 2.2A, phosphorylation of Erk1/2 was transiently induced, and
the maximal level of phosphorylated Erk1/2 was reached in 24 h, indicating a transient
activation of the Erk pathway by TCC.

98
Legend for Figure 2.2. Transient endpoints induced by TCC. (A) MCF10A (10A)
cells were treated with 200 nmol/L TCC (T) for the indicated periods. (B1 to B5) 10A
cells were exposed to TCC in the absence or presence of 10 µmol/L U0126 (U) or 5
mmol/L NAC (N) for 24 h. (C1 to C3) MCF7 and J82 cells were treated with 200
nmol/L TCC for 24 h. (A, B1, B2, & C1) Cell lysates were prepared and analyzed by
immunoblotting to detect levels of p-Erk1/2, Erk1/2, and Nox-1, with β-Actin as a
control, and these levels were quantified by densitometry. The level of specific
phosphorylation of Erk1/2 (p-Erk/Erk) was calculated by normalizing the level of pErk1/2 with the level of Erk1/2, then the level set in control cells as 1 (X, arbitrary unit).
The level of Nox-1 (Nox/Actin) was calculated by normalizing with the level of β-Actin
and the level set in control cells as 1 (X, arbitrary unit). (B3 & C2) Relative ROS levels
were measured with CM-H2DCF-DA labeling and normalized by the fluorescence
intensity determined in control cells, set as 1 (X, arbitrary unit). (B4) Relative cell
proliferation was determined and normalized by the value of BrdU detected in control
cells, set as 100%. (B5 & C3) Relative DNA damage was measured by a comet assay
and normalized by the value of average tail moment determined in control cells, set as 1
(X, arbitrary unit). Representative images of DNA damage in the comet assay are shown
in B5. Columns, mean of triplicates; bars, SD. Statistical significance is indicated by * P
< 0.05, ** P < 0.01. All results are representative of three independent experiments.
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Figure 2.2 Transient endpoints induced by TCC

100
Using the Mek inhibitor U0126 to block the Erk pathway, Nox-1 was reduced to a lower
level than in parental cells and TCC-exposed cells (Figure 2.2B1), indicating that TCC
induced Nox-1 through activation of the Erk pathway, thereby verifying the ability of
TCC to induce transient activation of the Erk-Nox pathway. Using NAC to block ROS,
we detected that the Erk-Nox pathway was suppressed in TCC-exposed cells (Figure
2.2B2), indicating ROS was induced by TCC in activation of the Erk-Nox pathway.
Additionally, blocking the Erk-Nox pathway by U0126 resulted in significant reduction
of TCC-induced ROS (Figure 2B3), suppression of ROS by NAC or U0126 resulted in
significant reduction of TCC-induced cell proliferation (Figure 2.2B4), and blockage of
the Erk-Nox pathway or ROS resulted in suppression of TCC-induced DNA damage
(Figure 2.2B5). These results indicate that TCC was able to induce the Erk-Nox pathway
and Nox-dependent ROS elevation, as well as Nox-independent ROS elevation to induce
increased cell proliferation and DNA damage. TCC-induced, Nox-independent ROS also
played a role in activation of the Erk-Nox pathway.
To address if TCC’s ability to induce these transient endpoints was limited to the
ER-negative MCF10A cells, we treated human breast cancer ER-positive MCF7 cells and
urinary bladder cancer J82 cells with TCC. We detected that TCC was able to induce the
Erk-Nox pathway (Figure 2C1), ROS elevation (2C2), and DNA damage (2C3) in both
types of human cancer cells. The results indicate that TCC-induced transient endpoints
were not specific to breast cells nor to ER status.
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2.4.3 Constitutive Endpoints Induced by TCC
To assess carcinogenic potency of TCC-exposed breast cells, we used the
tumorigenic P-20 cell line, which resulted from cumulative exposure of MCF10A cells to
PhIP for 20 cycles [33], and a highly-tumorigenic, oncogenic Ras-expressing MCF10ARas cell line [33,44] as controls. As performed previously, cumulative exposures of
MCF10A cells to 200 nmol/L TCC for 10 and 20 cycles resulted in T-10 and T-20 cell
lines, respectively. Then, we measured degrees of constitutive endpoints acquired by T10 and T-20 cells in comparison with P-20 and MCF10A-Ras cells. As shown in Figure
3, the constitutive endpoints of reduced dependence on growth factors (2.3A), anchorageindependent growth (2.3B), increased cell proliferation (3C), ROS elevation (2.3D), and
Mek-Erk-Nox pathway activation (3E) were increasingly induced in T-10 and T-20 cells
in an exposure-dependent manner; however, none of these constitutive endpoints was
induced to a comparable level to those acquired by tumorigenic P-20 and MCF10A-Ras
cells. Inoculation of T-20 cells into mammary fat pads of immunocompromised nu/nu
mice did not result in any xenograft tumors in 90 days in contrast to xenograft tumors
derived from P-20 and MCF10A-Ras cells, indicating that the T-20 cell line was not
tumorigenic (data not shown). These results indicate that long-term exposure to TCC
was able to induce cellular pre-malignancy.
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Legend for Figure 2.3. Constitutive endpoints induced by exposure to TCC.
MCF10A (10A) cells were repeatedly exposed to 200 nmol/L TCC for 10 and 20 cycles,
resulting in T-10 and T-20 cell lines, respectively. 10A cells were repeated exposed to 10
nM PhIP for 20 cycles to generate P-20 cells. 10A cells were stably transfected to
ectopically express oncogenic H-Ras, resulting in the MCF10A-Ras cell line (Ras). (A)
Cells were maintained in LM medium to determine acquired levels of reduced
dependence on growth factors (RDGF). (B) Cells were seeded in soft-agar to determine
acquired levels of anchorage-independent growth (AIG). (C) Relative cell proliferation
was determined and normalized by the value of BrdU detected in control parental cells,
set as 100%. (D) Relative ROS levels were measured with CM-H2DCF-DA labeling and
normalized by the fluorescence intensity determined in control parental cells, set as 1 (X,
arbitrary unit). (E) Cell lysates were prepared and analyzed by immunoblotting to detect
levels of p-Mek, Mek, p-Erk1/2, Erk1/2, and Nox-1, with β-Actin as a control, and these
levels were quantified by densitometry. The levels of specific phosphorylation of Mek
(p-Mek/Mek) and Erk1/2 (p-Erk/Erk) were calculated by normalizing the level of p-Mek
and p-Erk1/2 with the level of Mek and Erk1/2, respectively, then the level set in control
parental cells as 1 (X, arbitrary unit). The level of Nox-1 (Nox/Actin) was calculated by
normalizing with the level of β-Actin and the level set in control parental cells as 1 (X,
arbitrary unit). Columns, mean of triplicates; bars, SD. Statistical significance is
indicated by * P < 0.05, ** P < 0.01, *** P < 0.001. All results are representative of
three independent experiments.
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Figure 2.3: Constitutive endpoints induced by exposure to TCC.

104
2.4.4 Intervention of TCC-induced Carcinogenesis by Curcumin
Early intervention of cellular carcinogenesis from a non-cancerous stage to premalignant stages conceivably contributes to effective cancer prevention [2]. To identify
preventive agents effective in intervention of cellular pre-malignancy induced by chronic
exposure to TCC, we pursued agents, at non-cytotoxic levels, capable of blocking TCCinduced transient and constitutive endpoints in MCF10A cells. As shown in Figure 4A,
treatment of cells with curcumin at 10 and 20 µmol/L for 72 h resulted in significant
reduction of cell viability, but 0.1 or 1 µmol/L did not result in any detectable reduction
of cell viability. We used curcumin at the non-cytotoxic concentration of 1 µmol/L in the
following studies.
In studying if curcumin was able to block TCC-induced transient endpoints, we
detected that co-exposure MCF10A cells to 200 nmol/L TCC ane1 µmol/L curcumin
reduced TCC-induced activation of the Erk-Nox pathway (Figure 2.4B1). Curcumin
treatment also significantly reduced TCC-induced transient endpoints of ROS elevation
(Figure B2), increased cell proliferation (B3), and DNA damage (B4). These results
indicate that co-exposure to curcumin interfered in TCC-induced initiation of cellular
carcinogenesis in a single exposure. After 10 cycles of exposure, we detected that coexposure to curcumin significantly reduced TCC-induced constitutive endpoints of
reduced dependence on growth factors (Figure 2.4C1), anchorage-independent growth
(C2), increased cell proliferation (C3), and ROS elevation (C4), as well as activation of
the Erk-Nox pathway (C5); these constitutive endpoints were increased in T-10 cells but
reversed in curcumin-protected, T/C-10 cells. Accordingly, curcumin was effective in
the intervention of transient and constitutive endpoints induced by TCC in single and
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accumulated exposures, respectively. Thus, curcumin should be considered for early
intervention of TCC-induced, cellular pre-malignancy.
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Legend for Figure 2.4. Intervention of TCC-induced carcinogenesis by curcumin.
(A) MCF10A (10A) cells were treated with 0, 0.1, 10, and 20 µmol/L (µM) curcumin for
72 h. Quantification of cell viability in these cultures was determined with an MTT assay
kit. Relative cell viability was normalized by the value determined in control cells (0
µM), set as 100%. (B1 to B4) 10A cells were treated with 200 nmol/L TCC (T) in the
absence or presence of 1 µmol/L curcumin (C) for 24 h. (B1) Cell lysates were then
prepared and analyzed by Western immunoblotting to detect levels of p-Erk1/2, Erk1/2,
and Nox-1, with β-Actin as a control, and these levels were quantified by densitometry.
The level of specific phosphorylation of Erk1/2 (p-Erk/Erk) was calculated by
normalizing the level of p-Erk1/2 with the level of Erk1/2, then the level set in control
cells as 1 (X, arbitrary unit). The level of Nox-1 was calculated by normalizing with the
level of β-Actin and the level set in control cells as 1 (X, arbitrary unit). (B2) Relative
ROS levels were measured with CM-H2DCF-DA labeling and normalized by the
fluorescence intensity determined in control cells, set as 1 (X, arbitrary unit). (B3)
Relative cell proliferation was determined and normalized by the value of BrdU detected
in control cells, set as 100%. (B4) Relative DNA damage was measured by a comet
assay and normalized by the value of average tail moment determined in control cells, set
as 1 (X, arbitrary unit). (C1 to C4) 10A cells were repeatedly exposed to 200 nmol/L
TCC (T) in the absence and presence of 1 µmol/L of curcumin (C) for 10 cycles,
resulting in 10A, C-10, T-10, and T/C-10 cell lines. To determine levels of cellular
acquisition of reduced dependence on growth factors (RDGF) (C1) and anchorageindependent growth (AIG) (C2), cells were maintained in LM medium and seeded in
soft-agar, respectively. Cell colonies grown in LM medium and in soft-agar were
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counted. (C3) Relative cell proliferation was determined and normalized by the value of
BrdU detected in parental control cells, set as 100%. (C4) Relative ROS levels were
measured with CM-H2DCF-DA labeling and normalized by the fluorescence intensity
determined in parental control cells, set as 1 (X, arbitrary unit). (C5) Cell lysates were
prepared and analyzed by Western immunoblotting to detect levels of p-Erk1/2, Erk1/2,
and Nox-1, with β-Actin as a control, and these levels were quantified by densitometry.
The level of specific phosphorylation of Erk1/2 (p-Erk/Erk) was calculated by
normalizing the level of p-Erk1/2 with the level of Erk1/2, then the level set in parental
control cells as 1 (X, arbitrary unit). The level of Nox-1 was calculated by normalizing
with the level of β-Actin and the level set in control cells as 1 (X, arbitrary unit).).
Columns, mean of triplicates; bars, SD. Statistical significance is indicated by ** P <
0.01, *** P < 0.001. All results are representative of three independent experiments.
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Figure 2.4. Intervention of TCC-induced carcinogenesis by curcumin
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2.5 Conclusion
American lifestyles involve wide uses of cleaning agents containing TCC and
consumption of TCC-contaminated agricultural products. The role of TCC in increasing
breast cancer risk has been a concern; however, it has not yet been fully addressed. Our
model system revealed, for the first time, that cumulative exposures of human breast cells
to TCC at physiologically-achievable, nanomolar concentrations induced progressive
carcinogenesis from a non-cancerous stage to pre-malignant stages in a dose- and
exposure-dependent manner, suggesting the novel ability of TCC, as a co-carcinogen, to
induce breast cell pre-malignancy. Thus, the co-carcinogenic potential of low-dose TCC
should be seriously considered in epidemiological studies to reveal the significance of
TCC in the development of sporadic breast cancer. Using TCC-induced transient and
constitutive endpoints as targets will enable us to identify additional non-cytotoxic
preventive agents, such as curcumin, effective in suppressing TCC-induced cellular premalignancy. However, whether TCC is able to enhance malignancy with other
carcinogenic agents remains to be clarified.
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Chapter-III

TCC (3,4,4’- trichlorocarbanilide) enhances PhIP-induced breast cell carcinogenesis
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Research described in this chapter is slightly modified version of an article that will be
submitted to Molecular Carcinogenesis.
TCC (3,4,4’- trichlorocarbanilide) enhances PhIP-induced breast cell
carcinogenesis by Shilpa Sood, Shambhunath Choudhary, and Hwa-Chain Robert Wang
In this paper “our” and “we” refers to me and co-authors. My contribution in the
paper includes the following:
(1) Selection of the topic (2) Compiling and interpretation of the literature (3) Designing
experiments (4) understanding the literature and interpretation of the results (5) providing
comprehensive structure to the paper (6) Preparation of the graphs and figures (7)
Writing and editing
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3.1 Abstract
More than 85% of breast cancers are sporadic and attributable to long-term
exposure to environmental carcinogens and co-carcinogens. Few studies have been
conducted to study the role of co-carcinogens in potentiating the ability of environmental
carcinogens known to cause sporadic breast cancer. We sought to determine the activity
of triclocarban (TCC), an antimicrobial agent commonly used in household and personal
care products in enhancing PhIP-induced breast cell carcinogenesis. We have shown for
the first time that repeated co-exposures to both TCC and PhIP at bio-achievable
nanomolar levels effectively induced breast cell carcinogenesis of human breast epithelial
MCF10A cells from a non-cancerous stage to cancerous state in an in vitro model. The
degree of cellular carcinogenesis induced by chronic co-exposures to PhIP and TCC was
significantly higher than that induced upon chronic exposure to PhIP alone. Cellular
carcinogenesis upon co-treatment with TCC and PhIP was characterized by significant
increases in acquisition of cancer-associated properties of reduced dependence on growth
factors, anchorage-independent growth, increased cell proliferation, invasion and
migration as compared to chronic exposure to PhIP alone. These biological changes were
accompanied by biochemical and molecular changes, including the activation of the ErkNox pathway, and reactive oxygen species (ROS) elevation which were also significantly
higher than treatment with PhIP alone. Moreover, single simultaneous exposure of TCC
and PhIP also significantly induced transient induction of the Erk-Nox pathway, ROS
elevation, increased cell proliferation, and DNA damage which were higher as compare
to PhIP treatment alone. These constitutively- and transiently-induced endpoints were
effectively blocked by non-cytotoxic doses of mimosine and ergosterol. Our data

119
suggests that TCC can act as a co-carcinogen to potentiate PhIP-induced breast cell
carcinogenesis in in vitro study models. In addition, mimosine and ergosterol showed a
lot of potential as novel agents useful in the intervention of sporadic breast cancer as was
evidenced by suppression of transient and constitutive end points induced upon cotreatment with TCC and PhIP.
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3.2 Introduction
Breast cancer is the most common type of cancer among women in Europe and
North America and more than 85% of cases of breast cancer are sporadic in nature [1].
Exposure to environmental carcinogens is an important factor in the development of
sporadic breast cancer which is a multistep, multiyear, multipath disease process that
involves genetic and epigenetic alterations and progression from a non-cancerous stage to
a precancerous stage and ultimately leading to malignant breast cancer [2,3,4,5]. More
than 200 chemical carcinogens have been found to be capable of inducing acute
mammary carcinogenesis at high dosages in vitro and in vivo studies[5,6]. While
carcinogens induce cellular malignancy, co-carcinogens can either induce a state of cell
pre-malignancy or are capable to enhancing cellular malignancy. However, there is
limited amount of work on the role of co-carcinogens at their physiologically achievable
doses in enhancing the level of carcinogenesis induced upon chronic exposure to low
levels of environmental carcinogens, in an event of a co-exposure.
Our lab has developed a cellular model that helps to identify potential carcinogens and
co-carcinogens with the ability to induce breast cell carcinogenesis at their
physiologically relevant doses [7,8,9,10,11,12,13,14,15]. Our model mimics everyday
exposure of breast epithelial cells to environmental carcinogens and co-carcinogens at
physiologically relevant doses by identifying cellular, biochemical and molecular
transient and constitutive endpoints that are major drivers of initiation and progression of
breast cell carcinogenesis [11,12,14,15]. Our model also aids in identification of dietary
preventive agents that can effectively target these transient and constitutive endpoints
[9,10,11,12,13,14,15].
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Triclocarban (TCC), or 3,4,4'-trichlorocarbanilide, is an antibacterial agent commonly
used in personal care products such as disinfectants, soaps, body washes deodorants,
detergents, cleansing lotions, wipes etc [16]. TCC is an environmental pollutant and a
potential co-carcinogen (unpublished results) whose wide spread poses a great risk for
human health. Recent research has shown that TCC can act as an endocrine disrupter and
can augment the activities of certain steroid hormones [17, 18].
2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is heterocyclic amine
(HCAs) abundantly found in high temperature cooked meats particularly produced during
grilling and barbequeing procedures [19, 20, 21]. Consumption PhIP via such meats has
been associated with an enhanced risk of breast neoplasia by epidemiological studies [22;
23]. Several studies have reported that PhIP is genotoxic to human cells and a
concentration of PhIP as low as 450 nmol/L induced DNA adduct formation [21, 22, 23,
24]. Transient exposure of MCF10A cells at nanomolar doses of PhIP caused increased
cellular proliferation and activated the ERK pathway [25]. Recently, it was reported that
long-term exposure of breast cells to PhIP at physiologically-achievable, picomolar to
low nanomolar doses induced carcinogenesis and tumorigenicity [12]. Step wise
induction of carcinogenesis was accompanied by acquisition of cancer-associated
properties of reduced dependence on growth factors, anchorage-independent growth,
increased cellular proliferation, migration, invasion and carcinogenesis in mouse models
[12]. In addition an upregulated H-Ras gene expression, ERK pathway activation with
downstream elevation of Nox-1 expression, and elevated reactive oxygen species
production was noted. Co-exposure of environmental carcinogens at picomolar to
nanomolar doses can have an additive effect in the induction of breast cell carcinogenesis
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[11]. Whether simultaneous co-exposure of breast cells to PhIP and TCC can enhance
PhIP-induced breast cell carcinogenesis has not been addressed. Various polyphenolic
dietary components found to be present in a wide variety of fruits, vegetables, fruits have
been shown to possess anti-oxidant and antitumor activities such as suppressing
proliferation, induction of apoptosis. Moreover a lot many more naturally occurring
component with a potential to inhibit tumor formation need to explored. Ergosterol and
mimosine are two such promising compounds on the horizon whose anti tumorigenic
potential needs to evaluated.
Ergosterol forms a major constituent of fungal cell membranes and stimulates fungal
growth. It has been shown to possess antitumor activity attributed to its ability to inhibit
of angiogenesis in solid tumors [26]. Ergosterol extracted from Japanese edible
mushroom Hypsizigus marmoreus inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)
induced ear inflammation and tumor promotion in carcinogenesis mice models (27).
Various derivatives of ergosterol viz Ergosterol Peroxide (EP) found in lichens and
mushrooms possess immunosuppressive anti-viral, anti-inflammatory and anti-tumor
activities [28, 29, 30, 31]. However, the role of ergosterol and mimosine in sporadic
breast cancer prevention has not been previously determined.
Mimosine or leucenol is an alkaloid, β-3-hydroxy-4 pyridone amino acid, initially
isolated from Mimosa pudica. is also found to occur in some members of genus Mimosa
and all members of the related genus Leucaena [32]. Mimosine is an iron chelator and
that inhibits DNA synthesis and mammalian cell proliferation by blocking cell cycle at
the late G1 phase [33, 34, 35, 36]. It has been shown to inhibit cell proliferation in
prostate carcinoma cells [37]. In vitro and vivo studies have demonstrated that it has an
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anticancer effect on human lung cancer cells and xenografts [38, 39].Studies have been
conducted that gave an evidence of the ability of mimosine to suppress the growth of
human pancreatic cancer xenografts that were subcutaneously transplanted in nude mice
and a flow cytometric analysis of the tumor cells yielded a significantly increased sub-G1
fraction indicating occurrence of apoptosis [40].
Even though recent experimental data suggests that mimosine and ergosterol have a
potential anticancer activity, their role in the prevention of progressive cellular
carcinogenesis especially of breast tissue has not been addressed so far. So, this work
was undertaken with the objective of establishing the role of TCC as a co-carcinogen in
enhancing PhIP-induced breast cell carcinogenesis and to determine if mimosine and
ergosterol could suppress breast cell carcinogenesis induced by co-exposure to TCC and
PhIP.
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3.3 Materials and methods
3.3.1 Cell Cultures and Reagents
MCF10A (American Type Culture Collection [ATCC], Rockville, MD) and
derived cell lines were maintained in complete (CM) medium (1:1 mixture of DMEM
and HAM's F12, supplemented with 100 ng/mL cholera enterotoxin, 10 µg/mL insulin,
0.5 µg/mL hydrocortisol, 20 ng/mL epidermal growth factor, and 5% horse serum) [7, 8 ,
9, 10, 11, 12, 13, 14, 15]. Human breast cancer MCF7 and urinary bladder carcinoma
J82 cells (ATCC) were maintained in DMEM supplemented with 10% heat-inactivated
fetal bovine serum [lab ref]. All cultures were maintained in medium supplemented with
100 U/mL penicillin and 100 µg/mL streptomycin in 5% CO2 at 37°C. Stock aqueous
solutions of TCC (Sigma-Aldrich, St. Louis, MO), chloromethyldichlorodihydrofluorescein-diacetate (CM-H2DCF-DA) (Invitrogen, Carlsbad, CA),
U0126 (Cell Signaling, Beverly, MA), and curcumin (MP Biomedicals, Solon, Ohio)
were prepared in DMSO and diluted in culture medium. Stock aqueous solutions of Nacetyl-L-cysteine (NAC) (Alexis, San Diego, CA) were prepared in H2O and diluted in
culture medium for assays.

3.3.2 Chronic Induction of Cellular Carcinogenesis
Twenty-four hours after each subculturing, MCF10A cells were exposed to TCC
for 48 h, as one cycle of exposure for 10 to 20 cycles; cultures were subcultured every 3 d
[7, 8 , 9, 10, 11, 12, 13, 14, 15]. After exposures to TCC, cells were assayed to detect
acquired cancer-associated properties.
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3.3.3 Reduced dependence on growth factors
Five × 103 cells were seeded in 60-mm culture dishes and maintained in lowmitogen (LM) medium containing reduced total serum and mitogenic additives to 2% of
the concentration formulated in CM medium. Cell colonies (≥ 0.5 mm diameter) grown
in LM medium were counted microscopically [7, 8 , 9, 10, 11, 12, 13, 14, 15].

3.3.4 Anchorage-independent Growth
Five x 103 cells were mixed with soft-agar consisting of 0.4% SeaPlaque agarose
(Sigma-Aldrich) in a mixture (1:1) of CM medium with 3 d conditioned medium
prepared from MCF10A cultures, plated on top of the 2% SeaPlaque agarose base layer
in a 60-mm culture dish, and maintained for 20 d to develop cell clones. Cell colonies (≥
0.1 mm diameter) grown in soft-agar were counted microscopically [7, 8 , 9, 10, 11, 12,
13, 14, 15].

3.3.5 Cell Viability Assay
A Methyl Thiazolyl Tetrazolium (MTT) assay kit (ATCC) was used to measure
cell survivability in cultures. Five x 103 cells were seeded into each well of 96-well
culture plates for 24 h. After indicated treatments, cells were incubated with MTT
Reagent for 4 h, followed by incubation with detergent reagent for 24 h. Reduced MTT
reagent in cultures was quantified with an ELISA reader (Bio-Tek, Winooski, VT) [41,
42].
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3.3.6 Cell Proliferation
Cell proliferation was determined by of 5-bromo-2’-deoxyuridine (BrdU)
incorporation into cellular DNA using the BrdU cell proliferation ELISA kit (Roche,
Indianapolis, IN). Five x 103 cells were seeded into each well of 96-well culture plates
for 24 h. After treatment, cells were labeled with BrdU for 12 h, fixed, incubated with
peroxidase-conjugated BrdU-specific antibodies, and stained with peroxidase substrate.
Quantification of BrdU-labeled cells was determined with an ELISA reader (Bio-Tek)
[41, 42, 43].

3.3.7 Intracellular ROS Measurement
As performed previously [11,12,44], cells were incubated with 5 µmol/L CMH2DCF-DA for 1 h to detect ROS level by flow cytometry; the mean fluorescence
intensity of DCF was quantified using Multicycle software (Phoenix).

3.3.8 In vitro cell invasion and migration
The cell invasion assay was performed using 24-well Transwell insert-chambers with a
polycarbonate filter with a pore size of 8.0 µm (Costar, Corning, NY). Two x 104 cells in
serum-free medium were seeded on top of a Matrigel-coated filter (BD Biosciences) in
each insert-chamber. Then, insert-chambers were placed into wells on top of culture
medium containing 10% horse serum as a chemoattractant. The migration assay was
performed using 24-well Transwell insert-chambers with a polycarbonate filter without
Matrigel. The invasive or migratory ability of cells was determined by the number of
cells translocated to the lower side of filters [45, 11, 12].
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3.3.9 DNA Damage
DNA damage was measured by a comet assay [11, 12, 46]. Cells were mixed
with 1% low-melting agarose and placed on agarose-coated slides. Slides were then
immersed in lysis solution (1.2 mol/L NaCl, 100 mmol/L Na2EDTA, 1% Triton X-100,
and 0.3 nmol/L NaOH, pH 13) at 25°C for 1 h and rinsed three times with alkaline buffer
(2 mmol/L Na2EDTA and 300 mmol/L NaOH) for 20 min each. After electrophoresis in
the same alkaline buffer at 20V for 30 min, slides were stained with 2.5 µg/mL of
propidium iodide for 20 min and examined with a Zeiss fluorescence microscope
(Thornwood, NY) equipped with an excitation filter of 546 nm and barrier filter of 590
nm. Fifty nuclei per slide were scored for tail moment (% of DNA in the tail × tail
length) using CometScore software (Tritek, USA).

3.3.10 Western Immunoblotting
Equal amounts of cellular proteins were resolved by electrophoresis in 10% SDSpolyacrylamide gels and transferred to nitrocellulose filters for immunoblotting [47, 48,
49]. Specific antibodies were used to detect H-Ras, phosphorylated Mek (p-Mek), Mek,
phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, Nox-1, and β-Actin (Santa Cruz
Biotechnology, Santa Cruz, CA). Antigen-antibody complexes on filters were detected
by the Supersignal chemiluminescence kit (Pierce, Rockford, IL).

3.3.11 Statistical Analysis
The Student t test was used to analyze statistical significance, indicated by * P <
0.05, ** P < 0.01, *** P < 0.001; a P value of ≤ 0.05 was considered significant.
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3.4 Results
3.4.1 TCC-enances PhIP-induced breast cell carcinogenesis
Normal cells require growth factors for their survival and growth. In the absence of
growth factors cells undergo apoptosis [50, 51]. Normal cells also require cell adhesion
to extracellular matrix for survival and in its absence they die by a process of anoikis
[50]. Cells that progressively acquire abilities to grow under the limiting conditions of
reduced amounts of growth factors and absence of adhesion to extracellular matrix are
thought to have acquired tumorigenic potential. Moreover, anchorage–independent
growth and reduced dependence on growth factors are two important cancer-associated
properties and have been used to measure progressive carcinogenesis of non-cancerous
cells in response to exposure to environmental carcinogens [7, 8, 9, 10, 11, 12]. We used
these two cancer-associated properties as long-term targeted endpoints to determine
whether co-exposure of TCC and PhIP enhanced PhIP-induced breast cell carcinogenesis.
We repeatedly exposed MCF10A cells to either individual or combined TCC or PhIP
treatments at their physiologically achievable doses of 200 nM and 10 nM respectively
for 10 and 20 cycles (Fig 3.1). We detected that individual and combined treatments to
TCC and PhIP resulted in significant increase in number of surviving cell clones under
the conditions of reduced dependence of growth factors and anchorage independence
with increasing exposures (Fig 3.1A1-A2). Our results validated the previous published
data that PhIP at physiologically achievable doses of 10 nM induced breast cell
carcinogenesis in MCF 10 cells.
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Legend for Figure 3.1. TCC enhances PhIP-induced breast cell carcinogenesis
MCF10A cells were repeatedly exposed to individual (T, P) or combined TCC and PhIP
(TP) at 200 nmol/L and 10 nM/L respectively for 10, and 20 cycles. MCF10A cells were
stably transfected to ectopically express oncogenic H-Ras, resulting in the MCF10A-Ras
cell line (Ras). (A1) To determine acquisition of the cancer-associated property of
reduced dependence on growth factors (RDGF), cells were maintained in LM medium.
(A2) To determine acquisition of the cancer-associated property of anchorageindependent growth (AIG), cells were seeded in soft-agar. Cell colonies grown in LM
medium and soft-agar were counted microscopically. (B1) Relative ROS levels were
measured with CM-H2DCF-DA labeling and normalized by the fluorescence intensity
determined in control (10A) cells, set as 1 (X, arbitrary unit). (B2) Relative cell
proliferation was determined and normalized by the value of BrdU detected in MCF10A
cells, set as 100%. (B3) Migratory and (B4) invasive activities were determined by
counting the numbers of cells translocated through a polycarbonate filter without or with
coated Matrigel, respectively, in 10 arbitrary visual fields. Columns, mean of triplicates;
bars, standard deviation. The Student’s t test was used to analyze statistical significance,
indicated by * P < 0.05, ** P < 0.01, *** P < 0.001.
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Figure 3.1. TCC enhances PhIP-induced breast cell carcinogenesis.

131
More significantly, accumulated exposures to combined treatments additively increased
number of cell clones formed under the conditions of reduced dependence of growth
factors and anchorage–independent growth as compared to those formed after cumulative
exposures to PhIP or TCC alone (Fig 3.1A1-A2).
Since exposures of MCF10A cells to PhIP after 20 cycles resulted in fifty percent of mice
forming tumors in our earlier studies [12], we used twenty cycle exposed cells for our
further studies to determine the potential of TCC to confer additional carcinogenic
abilities to PhIP cells. We named MCF10A cells treated either individually or together
with TCC and PhIP as T20, P20 and TP20 cells respectively. We used MCF10A-Ras
cells, which are MCF10A cells with ectopic expression of oncogenic H-Ras, as positive
control for our studies. Our previous data had shown that P20 cells produced ROS,
proliferated at a higher degree and had higher abilities of invasion and migration as
compared to the MCF10A cells. We wanted to see if twenty cycles of co-exposure to
TCC and PhIP could enhance ROS production, cell proliferation, migration and invasion
potential of P20 cells. As shown in Figure 3.1B1-B4, TP20 cells produced higher
amounts of ROS, proliferated at higher degrees and had significantly higher abilities of
invasion and migration as compared to P20 cells but either comparable or significantly
less degrees as compared to MCF10A-Ras cells that served as a positive control. Hence,
our results showed that cumulative exposures to TCC could enhance breast cell
carcinogenesis induced by PhIP.
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3.4.2 Role of ERK pathway in TP-induced cancer associated properties
P20 cells have been shown to have higher expression of Ras, p-ERK, p-MEK and Nox-1
levels [12] and activation of Ras-Erk Nox pathway drove the progressive carcinogensis of
MCF10A cells from nonmalignant to premalignant to a malignant stage. We wanted to
see if co-exposure to TCC and PhIP would result in a higher activation of Ras ERK Nox
pathway. Twenty cycles of co-exposure to TCC and PhIP didn’t induce higher protein
levels of Ras than P20 cells (Fig 3.2A). However, TP20 cells had a higher expression of
p-Mek, p-Erk, Nox-1 protein as compared to P20 cells. So, TP20 cells had a higher
degree of activated Mek-Erk-Nox pathway as compared to P20 cells (Fig 3.2A). To
further validate the involvement of ERK pathway in inducing cancer associated
properties in TP20 cells, we found that inhibiting ERK pathway with U0 not only
blocked the activation of ERK pathway but also repressed elevated Nox-1 protein levels
(Fig 3.2B). U0 also blocked ROS and cell proliferation in TP20 cells (Fig 3.2B2-B3).
These results prove that ERK pathway played an important role in the enhanced
carcinogenic potential of TP20 cells as compared to P20 cells.
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Legend for Figure 3.2. Role of ERK Pathway in modulation of TP-induced cancerassociated properties. MCF10A cells were repeatedly exposed to individual (T, P) or
combined TCC and PhIP (TP) at 200 nmol/L and 10 nM/L respectively for 20 cycles.
MCF10A cells were stably transfected to ectopically express oncogenic H-Ras, resulting
in the MCF10A-Ras cell line (Ras). (A) Lysates from cells exposed to TCC or PhIP
individually or together for 20 cycles were prepared and analyzed by immunoblotting
using specific antibodies to detect levels of phosphorylated Mek1/2 (p-Mek1/2), Mek1/2,
phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, Nox-1, with β-Actin as a control. The level of
specific phosphorylation of Mek1/2 (p-Mek1/2) was calculated by normalizing the level
of p-Mek1/2 with the level of Mek1/2, then the level set in MCF10A cells as 1 (X,
arbitrary unit). The level of specific phosphorylation of Erk1/2 (p-Erk1/2) was calculated
by normalizing the level of p-Erk1/2 with the level of Erk1/2, then the level set in
MCF10A cells as 1 (X, arbitrary unit). The levels of Nox-1 were calculated by
normalizing with the level of β-Actin, the level set in MCF10A cells as 1 (X, arbitrary
unit). All results are representative of three independent experiments. (B1-B3) MCF10A
andTP20 cells were treated without or with 10 µM/L U0126 (U) for 48 h. (B1) Cell
lysates were prepared and analyzed by immunoblotting to detect levels of phosphorylated
Erk1/2 (p-Erk1/2), Erk1/2, and Nox-1, with β-Actin as a control, and these levels were
quantified by densitometry. The levels of Nox-1 were calculated by normalizing with the
level of β-Actin and the level set in untreated control cells as 1 (X, arbitrary unit). The
levels of specific phosphorylation of Erk1/2 (p-Erk1/2) were calculated by normalizing
the levels of p-Erk1/2 with the levels of Erk1/2 , then the level set in control cells as 1 (X,
arbitrary unit). (B2) ROS levels were measured with CM-H2DCF-DA labeling; relative
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level of ROS, as fold induction (X, arbitrary unit), was normalized by the level
determined in MCF10A cells, set as 1. (B3) Cell proliferation was determined; relative
cell growth rate was normalized by the value of BrdU detected in MCF10A cells, set as
100%. Columns, mean of triplicates; bars, standard deviation. The Student’s t test was
used to analyze statistical significance, indicated by * P < 0.05, ** P < 0.01, *** P <
0.001. All results are representative of three independent experiments.
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Figure 3.2 Role of ERK Pathway in modulation of TP-induced cancer-associated
properties
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3.4.3 TCC enhances PhIP-induced transient endpoints
To investigate the mechanisms underlying chronic carcinogenesis induced by
simultaneous treatments with PhIP and TCC in MCF10A cells, and to determine if short
term treatment with TCC also enhanced, PhIP-induced transient endpoints in MCF10A
cells and thus contributed towards enhancement of PhIP-induced cellular carcinogenesis
by TCC in TP20 cells, we subjected MCF10A cells to single exposure of TCC and PhIP
at their bio-achievable doses. First of all, we wanted to determine the time of maximum
activation of ERK pathway after co-treatment with TCC and PhIP. PhIP has been shown
to induce maximum p-ERK levels in 24 hours. As can be seen in Figure 3.3A, combined
treatment of PhIP and TCC induced maximal levels of p-ERK after 24 hours of the cotreatment. We chose this time interval for our further experiments. We have also shown
earlier that 24 h of PhIP treatment leads to a transient upregulation of HRas protein and
also induced downstream ERK-Nox pathway [12]. We wanted to investigate whether coexposure of TCC and PhIP would elevate the protein expression of HRas and activation
of downstream ERK-Nox pathway. As we can see in Figure 3.3B, short-term treatment
of MCF10A cells with PhIP and TCC didn’t cause any changes in HRas expression levels
induced by PhIP. However, we found that co-treatment of TCC and PhIP were able to
additively enhance protein expression of phosphorylated Erk1/2 levels and Nox-1 levels
induced by PhIP. Moreover, upon blocking ERK pathway by use of inhibitors like U0,
ERK-Nox activation was blocked. In our previous study, we had shown that PhIPinduced transient activation of ERK pathway leading to ROS elevation which increased
cell proliferation in MCF10A cells [12].
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Legend for Figure 3.3. Short-term targeted endpoints: TCC enhances ROS
elevation, ERK pathway, cell proliferation, and DNA damage transiently induced by
short term exposure to PhIP. (A) MCF10A (10A) cells were coexposed to 200 nmol/L
TCC (T) and 10 nM PhIP (P) for the indicated periods. (B) MCF10A cells were treated
either individually (T, P) or together (TP) with 200 nmol/L TCC (T) and 10 nM PhIP (P)
for 24 h. (C) MCF10A cells were treated either individually (T, P) or together (TP) with
200 nmol/L TCC (T) and 10 nM PhIP (P) for 24 h in the absence or presence 10 µmol/L
U0126 (U). (A-C) Cell lysates were prepared and analyzed by Western immunoblotting
to detect levels of p-Erk1/2, Erk1/2, and Nox-1, with β-Actin as a control, and these
levels were quantified by densitometry. The levels of Nox-1 were calculated by
normalizing with the level of β-Actin and the level set in untreated control cells as 1 (X,
arbitrary unit). The levels of specific phosphorylation of Erk1/2 (p-Erk1/2) were
calculated by normalizing the levels of p-Erk1/2 with the levels of Erk1/2, then the level
set in control cells as 1 (X, arbitrary unit). (D1-D3) MCF10A (10A) cells were treated
either individually (T, P) or together (TP) with 200 nmol/L TCC (T) and 10 nM PhIP (P)
in the absence or presence of 10 µmol/L U0126 (U), 5 mmol/L NAC (N) for 24 h. (D1)
Relative ROS levels were measured with CM-H2DCF-DA labeling and normalized by the
fluorescence intensity determined in untreated cells, set as 1 (X, arbitrary unit). (D2)
Relative cell proliferation was determined and normalized by the value of BrdU detected
in untreated cells, set as 100%. (D3) Relative DNA damage was measured by a comet
assay and normalized by the value of average tail moment determined in untreated
counterpart cells, set as 1 (X, arbitrary unit). (E1) To determine reduced dependence on
growth factors (RDGF) cells were maintained in LM medium. (E2) To determine
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anchorage-independent growth (AIG), cells were seeded in soft-agar. Representative
images of DNA damage in the comet assay are shown. (E1-E2) MCF10A (10A) cells
were repeatedly exposed to 200 nM TCC and 10 nmol/L PhIP in the absence and
presence of 2 µmol/L U0126 (U), for 5 cycles, resulting in 10A, TP5, TP5/U5 cell lines
respectively. Columns, mean of triplicates; bars, standard deviation. The Student’s t test
was used to analyze statistical significance, indicated by * P < 0.05, ** P < 0.01, *** P <
0.001. All results are representative of three independent experiments.
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Figure 3.3. Short-term targeted endpoints: TCC enhances ROS elevation, ERK
pathway, cell proliferation, and DNA damage transiently induced by short term
exposure to PhIP
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Increased ROS production was responsible for inducing DNA damage. We wanted to
determine whether TCC can potentiate PhIP’s ability to cause ROS production, cell
proliferation and induce DNA damage after transient co-exposure with TCC and PhIP.
As shown in figure 3.3D1-3.3D3, TCC significantly enhanced PhIP-induced ROS
production, cell proliferation and DNA damage which was suppressed by blocking ERK
Pathway and ROS production using U0 and NAC respectively. These results indicate
that ERK pathway and ROS played important role in TCC’s ability to enhance PhIPinduced transient targeted endpoints.
This proves that TCC increased transient induction of the Erk-Nox pathway to cause
ROS elevation and cellular proliferation, induced by PhIP treatment with each exposure
cycle. Hence, cumulative co-exposures to TCC and PhIP increased the accumulation of
DNA damage caused by PhIP treatment alone leading to an enhanced level of progressive
carcinogenesis in PhIP treated cells.
To further validate the role of ERK pathway in TP-induced carcinogenesis, we treated
MCF10A cells with TCC and PhIP in the presence and absence of U0(U) for five
consecutive exposure cycles to generate 10A, U5, TP5 and TP/U5 cells. We found that
U0 was able to repress number of colonies formed under the conditions of reduced
dependence of growth factors and anchorage-independent growth in MCF10A cells cotreated with TCC and PhIP for 5 cycles(Fig 3.3E). These data show that co-exposure to
TCC and PhIP potentiated the degree of transient as well as constitutive endpoints
induced by treatment with PhIP alone and that activated ERK pathway played an
important role in potentiating initiation and progression of PhIP-induced carcinogenesis
by co-treatment with TCC and PhIP.
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3.4.4 TCC enhanced PhIP-induced transient endpoints in breast carcinoma and
bladder cancer cells.
To investigate if TCC’s ability to enhance the degree of PhIP-induced transient endpoints
was not limited to MCF10A cells, we subjected breast carcinoma MCF7 cells and bladder
cancer J82 cells to a single exposure of physiologically achievable doses of TCC and
PhIP. Co-exposure to TCC and PhIP was able to induce Erk-Nox pathway (Fig3 4A)
leading to ROS elevation (Fig 3.4B) and DNA damage (Fig 3.4C) in MCF7 and J82 cells.
More importantly, combined exposure significantly enhanced the ability of PhIP to
activate ERK Nox pathway, ROS production and cell proliferation. This shows that cotreatment with TCC has the similar effect of potentiating PhIP-induced activation of the
ERK Pathway in other types of cell lines. These results also show that TCC induced
transient endpoints not only in non-cancerous, ER-negative MCF10A cells but also in the
ER-positive cancerous MCF7 cells. Therefore, TCC –induced potentiation of cellular
carcinogenesis due to PhIP exposure is independent of ER- status of the cells.
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Legend for Figure 3.4. TCC enhances PhIP-induced ERK Pathway activation, ROS
elevation, and DNA damage in breast carcinoma and bladder cancer cells. (A-C)
MCF7 and J82 cells were exposed to individual (T, P) or combined TCC and PhIP (TP)
at 200 nmol/L and 10 nM/L respectively for 24 h. (A) Cell lysates were prepared and
analyzed by immunoblotting to detect levels of p-Erk1/2, Erk1/2, and Nox-1, with βActin as a control, and these levels were quantified by densitometry. The level of
specific phosphorylation of Erk1/2 (p-Erk1/2) was calculated by normalizing the level of
p-Erk1/2 with the level of Erk1/2, then the level set in control cells as 1 (X, arbitrary
unit). The level of Nox-1 (Nox/Actin) was calculated by normalizing with the level of βActin and the level set in control cells as 1 (X, arbitrary unit). (B) Relative ROS levels
were measured with CM-H2DCF-DA labeling and normalized by the fluorescence
intensity determined in control cells, set as 1 (X, arbitrary unit). (C) Relative DNA
damage was measured by a comet assay and normalized by the value of average tail
moment determined in control cells, set as 1 (X, arbitrary unit). Columns, mean of
triplicates; bars, SD. Statistical significance is indicated by * P < 0.05, ** P < 0.01, ***
P < 0.001. All results are representative of three independent experiments.
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Figure 3. TCC enhances PhIP-induced ERK Pathway activation, ROS elevation,
and DNA damage in breast carcinoma and bladder cancer cells.
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3.4.5 Mimosine and ergosterol suppression of TP-induced short-term targeted
endpoints
To first determine the non-cytotoxic doses of ergosterol and mimosine, we studied
cytotoxicity of these two compounds in MCF10A cells. As shown in the figure 3.5A1
and3 5A2, treatment of MCF10A cells with either ergosterol or mimosine at
concentrations of 100 nM or more significantly reduced cell viability. However,
treatment with neither mimosine nor ergosterol at 10 nM induced any detectable
reduction in cell viability. So, we used 10 nM ergosterol or mimosine in our subsequent
studies. To study whether ergosterol or mimosine could block combined TCC and PhIPinduced initiation of carcinogenesis, we exposed MCF10A cells to either DMSO or TCC
and PhIP together in the presence and absence of these two compounds for 24 h. As
shown (Fig3.5B1-B4), both ergosterol and mimosine were able to suppress simultaneous
TCC and PhIP treatment induced transient phosphorylation of Erk1/2, induction of Nox1, ROS elevation, increased cell proliferation, and DNA damage. These results indicate
that ergosterol and mimosine at non cytotoxic concentrations could block combined TCC
and PhIP-induced transient endpoints of breast cell carcinogenesis.
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Legend for Figure 3.5. Mimosine and ergosterol suppression of TP-induced short
term targeted endpoints. (A1) MCF10A cells were treated with 0, 100 pM, 1 nM, 10
nM, 100 nM, 1 µM, 10 µM and 20 µmol/L ergosterol (E) for 72 h. Quantification of cell
viability in these cultures was done with an MTT assay kit. Relative cell viability was
normalized by the value determined in untreated cells, set as 100%. Columns, mean of
triplicates; bars, SD. (A2) MCF10A (10A) cells were treated with 0, 100 pM, 1 nM, 10
nM, 100 nM, 1 µM, 10 µM and 20 µmol/L mimosine (M) for 72 h. Cell viability in these
cultures was determined with an MTT assay kit. Relative cell viability was normalized
by the value determined in untreated cells, set as 100%. Columns, mean of triplicates;
bars, SD. (B1-B4) MCF10A (10A) cells were treated with 200 nmol/L TCC (T) and 10
nmol/L PhIP (P) together (TP) in the absence or presence of 10 nmol/L ergosterol (E) or
10 nmol/L mimosine (M) for 24 h. (B1) Cell lysates were then prepared and analyzed by
Western immunoblotting to detect levels of specific phosphorylation of Erk1/2 (pErk1/2), Erk1/2, and Nox-1, with β-Actin as a control, and these levels were quantified
by densitometry. The level of Nox-1 were calculated by normalizing with the level of βActin and the level set in control MCF10A cells as 1 (X, arbitrary unit). The level of
specific phosphorylation of Erk1/2 (p-Erk1/2) was calculated by normalizing the level of
p-Erk1/2 with the level of Erk1/2, then the level set in MCF10A cells as 1 (X, arbitrary
unit). (B2) Relative ROS levels were measured with CM-H2DCF-DA labeling and
normalized by the fluorescence intensity determined in MCF10A cells, set as 1 (X,
arbitrary unit). (B3) Relative cell proliferation was determined and normalized by the
value of BrdU detected in MCF10A cells, set as 100%. (B4) Relative DNA damage was
measured by a comet assay and normalized by the value of average tail moment
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determined in untreated counterpart cells, set as 1 (X, arbitrary unit). Columns, mean of
triplicates; bars, standard deviation. The Student’s t test was used to analyze statistical
significance, indicated by ** P < 0.01, *** P < 0.001. All results are representative of
three independent experiments.
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Figure 3.5. Mimosine and ergosterol suppression of TP-induced short term targeted
endpoints
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3.4.6 Intervention of TP-induced chronic cell carcinogenesis by mimosine and
ergosterol

To determine whether mimosine and ergosterol could suppress chronic cellular
carcinogenesis induced by co-exposure to TCC and PhIP, MCF10A cells were exposed to
either DMSO or PhIP and TCC together, in the absence and presence of ergosterol and
mimosine for 10 cycles to yield 10A, E10, M10, TP10, TP/E10 and TP/M10 cells
respectively. Cells co-exposed to TCC and PhIP after 10 cycles exhibited higher degrees
of cancer-associated properties of anchorage-independent growth and reduced
dependence on growth factors which were significantly reduced by mimosine and
ergosterol co-treatment (Figure 3.6A and 3.6B). Moreover, mimosine and ergosterol
reduced combined PhIP and TCC-induced constitutively increased ROS production and
cell proliferation in TP10 cells (Figure 3.6C-3.6D). We also found that chronically
induced Erk-Nox pathway in TP10 cells was suppressed by both ergosterol and mimosine
(Figure 3.6E). These results indicate that mimosine and ergosterol were able to block
TCC and PhIP-induced chronic cellular carcinogenesis. So, they are new promising
agents that can be useful in the prevention of sporadic breast cancer.
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Legend for Figure 3.6. Intervention of TP-induced chronic breast cell
carcinogenesis by ergosterol and mimosine. (A-E) MCF10A (10A) cultures were
repeatedly exposed to either DMSO or 200 nmol/L TCC and 10 nmol/L PhIP together
(TP) in the absence and presence of 10nM/L ergosterol (E)or 10 nM/L mimosine (M) for
10 cycles, resulting in 10A, E10, M10, TP10, TP/E10 and TP/M10 cell lines,
respectively. To determine reduced dependence on growth factors (RDGF) (A) and
anchorage-independent growth (AIG) (B), cells were maintained in LM medium and
seeded in soft-agar respectively. Cell colonies grown in LM medium and soft-agar were
counted. (C) Relative ROS levels were measured with CM-H2DCF-DA labeling and
normalized by the fluorescence intensity determined in MCF10A cells, set as 1 (X,
arbitrary unit). (D) Relative cell proliferation was determined and normalized by the
value of BrdU detected in MCF10A cells, set as 100%. (E) Cell lysates were prepared
and analyzed by Western immunoblotting to detect levels of Erk1/2 phosphorylation (pErk1/2), Erk1/2, and Nox-1, with β-Actin as a control, and these levels were quantified
by densitometry. The level of Nox-1 were calculated by normalizing with the level of βActin and the level set in control MCF10A cells as 1 (X, arbitrary unit). The level of
specific phosphorylation of Erk1/2 (p-Erk1/2) was calculated by normalizing the level of
p-Erk1/2 with the level of Erk1/2, then the level set in MCF10A cells as 1 (X, arbitrary
unit). Columns, mean of triplicates; bars, standard deviation. The Student’s t test was
used to analyze statistical significance, indicated by ** P < 0.01, *** P < 0.001. All
results are representative of three independent experiments.
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Figure 3.6. Intervention of TP-induced chronic breast cellular carcinogenesis by
ergosterol and mimosine.
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3.5 Discussion
Human body is constantly exposed to different kinds of pollutants on a day to day basis
through a variety of ways for example, through diet and use of personal care products.
Exposure to some of the known carcinogens like consumption of PhIP through over
cooked meat has been shown to have the potential to cause breast carcinogenesis. Many
of the constituents used in the manufacture of personal care products like TCC are under
the scanner for their capability to cause breast cancer or act as a co-carcinogen whwereby
they enhance the potential of other carcinogens like PhIP in causing breast cancer. In this
study we wanted to determine whether TCC has the ability to enhance the initiation and
progression of malignant breast cell carcinogenesis caused by PhIP. We have developed
a model system in our lab which has shown a remarkable ability to detect induction and
progression of chronic breast cell carcinogenesis by repeated exposures to
physiologically relevant doses of environmental carcinogens like NNK, B[a]P and PhIP
[11,12]. In contrast to other cell systems that utilize high dose regimens in the
micromolar to millimolar ranges to acutely induce carcinogenesis, our model system
relies on bio-achievable nanomolar to picomolar concentrations of carcinogens to study
progressive cellular carcinogenesis [8,9,10,11,12]. In addition, our model system has
shown the potential to identify naturally occurring agents that are easily consumed
through daily diet at their non-cytotoxic doses, which have the capability to intervene
breast cell carcinogenesis induced by repeated exposures to environmental agents. In the
present study, we utilized our unique model system to identify the roles of mimosine and
ergosterol in suppressing chronic breast cellular carcinogenesis induced by co-treatment
of TCC and PhIP. Our model system also revealed the mechanisms behind the ability of
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mimosine and ergosterol to target the process of chronic carcinogenesis induced by coexposure to TCC and PhIP at biological, biochemical and molecular levels. Hence our
model system will help in identification of additional carcinogens, co-carcinogens and
preventive agents capable of induction and intervention of sporadic breast cancer.
Using certain biological, biochemical and molecular transient and constitutive targeted
endpoints, we determined that TCC potentiated the ability of PhIP to initiate and progress
the process of cellular carcinogenesis in MCF10A cells. MCF10A cells co-exposed to
PhIP and TCC (TP20) acquired higher levels of cancer-associated properties, ROS
generation potential, proliferation, migration and invasion capabilities as compared to
P20 cells and these properties were comparable to that of MCF10A-Ras cells. Cotreatment with TCC and PhIP for 20 cycles did not increase Ras protein expression in
TP20 cells when compared to Ras expression level in P20 cells. However,
phosphorylated Mek, phosphorylated Erk and Nox-1 levels were enhanced leading to
significantly higher ROS production and cell proliferation. Also, co-exposure of PhIP
and TCC was able to induce ROS in a Ras-independent manner. Therefore, ROS
generated via a Ras-independent manner was responsible for enhancing PhIP-induced
activation of ERK pathway, ROS production, cell proliferation and DNA damage in cells
simultaneously treated with TCC and PhIP. However, the mechanism behind Rasindependent induction of ROS that contributed towards enhancement of TP-induced
carcinogenesis remains to be studied. Moreover, our study has shown that mimosine and
ergosterol were able to block breast cell carcinogenesis induced by simultaneous
treatment with PhIP and TCC. This study reveals for the first time the role of TCC as a
co-carcinogen in enhancing PhIP-induced breast cell carcinogenesis in an in-vitro model.
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Chapter 4
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4.1 Summary
An overwhelming majority of breast cancers are sporadic in nature attributable to chronic
exposure to environmental factors, through a multi-year, multi-step, and multi-path
process involving genetic and epigenetic alterations leading to progressive development
from a non cancerous stage to premalignant and ultimately malignant breast cancer.
Most current studies for induction of carcinogenesis involve use of high doses of
carcinogens in their micromolar to millimolar doses to acutely induce cancers. However,
this does not truly reflect the physiological process of carcinogenesis which involves low
dose exposure to carcinogens. In the present study, I used a model that mirrors the actual
carcinogenesis process by using a low dose exposure strategy in which normal breast
epithelial MCFA cells are exposed to physiologically achievable doses of co-carcinogens
and carcinogens over multiple passages (cycles). The experimental scheme which I used
for my work is shown in Figure 4.1. MCF10A cells were exposed to either TCC, PhIP
alone or together, in the absence or presence of preventive agents like curcumin,
ergosterol or mimosine for 10-20 cycles. After the multiple exposures to either TCC or
PhIP individually or together, the cells were analysed for acquisition of cancer associated
properties of reduced dependence on growth factors and anchorage independent growth.
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Figure 4.1 Experimental Scheme of induction of premalignant breast cellular
carciniogenesis and intervention
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Cells were also evaluated for acquisition of cetain molecular endpoints.as shown in
Figure 4.2. These endpoints included activation of the Erk pathway with increased
phospho-Erk and down stream Nox-1 protein levels, increased cell proliferation and ROS
production. My hypothesis was that long-term exposure to TCC can induce breast cell
carcinogenesis and co-exposure to TCC and PhIP can enhance PhIP-induced breast cell
carcinogenesis which can be prevented using curcumin, ergosterol and mimosine.
First of all, I wanted to determine if chronic exposure to physiologically achievable doses
of TCC would cause breast epithelial cells to acquire the cancer-associated properties and
also wanted to evaluate the potential of curcumin in the intervention of TCC-induced
breast cell carcinogenesis. Working towards these objectives, I treated MCF10A cells
with TCC for 10-20 cycles with three different doses of TCC including the bioachievable
dose of 200 nM. It was observed that there was induction of acquisition of cancerassociated properties of reduced dependence on growth factors and anchorage–
independent growth in cells treated with TCC in a dose and exposure dependent manner
with activation of Erk-Nox pathway. These changes were constitutively induced in
response to chronic TCC treatment. Even though physiologically achievable 200 nM was
found to induce significant premalignant breast cell carcinogenesis related changes in
MCF10A cells after 20 cycle of exposure, these T20 cells were not found to be
tumorigenic in nude mice. Single exposure of TCC to MCF10A cells was also found to
induce transient endpoints of Erk pathway activation, enhanced ROS production, cellular
proliferation and DNA damge. Inhibiting Erk pathway and ROS suppressed transient as
well as constitutive endpoints induced by TCC. Curcumin at noncytotoxic dose of 1uM
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was tested for its ability to impede TCC-induced transient and constitutive endpoints in
MCF10A cells.
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Figure 4.2 Targeted Molecular endpoints in breast cell carcinogenesis
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It was observed that curcumin suppressed TCC-induced cancer associated properties of
reduced dependence on growth factors, anchorage independent growth and also
suppressed constitutive and transiently induced cell proliferation and ROS production,
erk pathway activation. Co-treatment with curcumin also caused significant reduction in
TCC induced DNA damage in MCF 10A cells.
To further study the potential of TCC to act as a co-carcinogen, I sought to determine if
TCC could enhance PhIP-induced breast cell carcinogenesis and also wanted to
determine whether mimosine and ergosterol could block breast cell carcinogenesis
induced by co-treatment with TCC and PhIP. MCF10A cells were treated with
bioachievable doses of PhIP and TCC either individually or together for 10 and 20
cycles. Validating previous results, I found that cells treated with either PhIP or TCC
induced formation of significantly higher number of cell clones when compared to the
untreated control cells. More importantly however, co-treating cells with PhIP and TCC
significantly increased the level of cancer-associated properties acquired by these cells
when compared to the cells treated with PhIP or TCC alone. Similarly, simultaneous
TCC and PhIP treatment for twenty cycles was found to enhance migration, invasion, cell
proliferation and ROS generation capabilities of cells treated for 20 cycles with PhIP
alone. Chronic TCC and PhIP co-treatment was able to activate Erk-Nox pathway to a
higher level as compared to cells treated with PhIP alone. These results indicated that
TCC was able to significantly enhance breast cell carcinogenesis induced by PhIP alone.
Erk pathway was found to play an important role in chronic breast cell carcinogenesis
induced by co-exposure to TCC and PhIP since its inhibition blocked breast cell
carcinogenesis induced by treatment with TCC and PhIP. To find the underlying
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mechanism of breast cell carcinogenesis induced by the co-exposure to TCC and PhIP,
cells were treated with TCC and PhIP for 24 h to see if transient end points of
carcinogenesis were induced. The results indicated that co-treatment caused activation of
Erk-Nox pathway in MCF10A cells to a higher level as compared to that induced by
individual treatment with PhIP. In the similar manner, co-treatmet with both the
compounds also induced significanty higher levels of ROS, cell proliferation and DNA
damage as compared to cells treated with PhIP alone. These results proved that cotreatment with TCC and PhIP significantly potentiated the ability of PhIP to induce
transient end points of breast cell carcinogenesis in MCF10A cells and thus contributed
towards enhancing its ability to potentiate chronic breast cell carciniogenesis caused by
co-exposure to TCC and PhIP. Similar changes were also seen when MCF7 and J82 cells
were subjected to TCC and PhIP together for a single exposure. These results indicated
that TCC was able to augment PhIP-induced constitutive and transient endpoints of breast
cell carcinogenesis. Next, in order to evaluate the ability of mimosine and ergosterol to
suppress breast cell carcinogenesis induced by co-exposure to TCC and PhIP, MCF10A
cells were co-treated with TCC and PhIP in the absence and presence of non cytotoxic
concentrations of ergosterol and mimosine in long term exposure for 10 cycles as well as
short-term exposure for a single cycle. Results indicated that both mimosine and
ergosterol inhibited acquisition of cancer-associated properties of anchorage-independent
growth, reduced dependence on growth factors induced by co-exposure to TCC and PhIP.
Simultaneous treatment with preventive agents also suppressed chronic increase in cell
proliferation, ROS production and Erk-Nox activation induced upon co-treatment with
TCC and PhIP. Transient endpoints of Erk pathway activation, ROS production, cell
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proliferation and DNA damage were also suppressed by the two preventive agents.
These results prove that ergosterol and mimosine were effective in suppressing breast cell
carcinogensis induced by co-treatment with TCC and PhIP.

To conclude, this study has demonstrated that cumulative exposures of non cancerous
human breast epithelial cells MCF10A, with physiologically achievable doses of
triclocarban induced cancer-associated properties of reduced dependence on growth
factors, anchorage-independent growth in MCF10A cells. The premalignant breast
cellular carcinogenesis induced by TCC was characterized by activation of ERK
pathway, ROS production, DNA damage and increased cellular proliferation. Curcumin,
a dietary component of turmeric, easily ingested in the form of curry powder at non
cytotoxic concentrations inhibited acquisition of cancer-associated properties in MCF10A
cells and blocked pre-malignant carcinogenesis induced by cumulative exposures to
TCC. TCC also enhanced PhIP–induced breast cell carcinogenesis by significantly
increasing the degree of cancer-associated properties attained by cells treated with PhIP
alone. Erk pathway activation played a major role in breast cell carcinogenesis induced
by co-exposure to TCC and PhIP in MCF10A cells. Ergosterol and mimosine at their
low nanomolar noncytotoxic concentrations intervened with this TCC and PhIP coexposure induced breast cell carcinogenesis in a significant manner. The mechanism of
breast cell carcinogenesis and prevention is summarized in the scheme shown in Figure
4.3. Exposure to TCC and PhIP induces increased expression of phospho-Erk in a Ras
independent manner. Erk activation causes increased expression of downstream Nox-1
which leads to increase in ROS production.

168

Figure 4.3 Schematic summary of breast carcinogenesis induced by TCC and
PhIPand its intervention
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Treatment with these compounds also causes increased ROS production in a Nox-1
independent manner possibly via mitochondriawhich also contributes towards activation
of Ras independent Erk pathway. Finally, ROS production and Erk pathway activation
causes increased cell proliferation leading to DNA damage and breast cell carcinogenesis.
Use of preventive agents in the form of curcumin, ergosterol and mimosine intervened
with Erk pathway activation, ROS production, increased cell proliferation, DNA damage,
ultimately leading to suppression of breast cell carcinogenesis.

4.2 Future directions
Our study shows that TCC elevated ROS production in breast epithelial cells and induced
the ERK pathway in a Ras independent manner. However, how this portion of ROS was
induced by TCC in MCF10A and MCF7 cells and how ROS was able to induce Rasindependent activation of Mek1/2 and Erk1/2 remain to be determined. We have shown
the co-exposure of MCF10A cells to TCC and PhIP at physiological concentrations for
20 cycles can enhance various invitro cancer-associated properties, but this could not
potentiate tumorigenic potential of PhIP in mice models, therefore it is important to
identify if further co-treatments with TCC and or treatment with other carcinogens will
make cells significantly more tumorigenic than P20 cells. Also, it needs to be determined
whether TCC can potentite PhIP-induced EMT (epithelial to mesenchymal transition) in
MCF10A cells. For example, whether TCC can cause an increase in Aldehyde
dehydrogenase (ADLH)-positive and mammosphere populations induced by PhIP
treatment of MCF10A cells and alter other markers of metastasis induced by PhIP
treatment like causing changes in expression of E-cadherin, Epithelial cell adhesion
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molecule (EpCAM) , matrix metallo proteinase (MMP)-9, and vimentin. Also, it needs
to be studied, whether there are other dietary agents that can intervene with TCC-induced
or TP-induced breast cellular carcinogenesis.
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